Archived Medical News Stories

Archived Drug Trial News Stories - 2010

Date	Title	Comments	Rating
2010-12-30	Immunitor reports positive safety imm01 clinical trial against tuberculosis	0	None
2010-12-30	Enrollment commences in belinostat-Tarceva combination trial for NSCLC	0	None
2010-12-29	Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC	0	None
2010-12-29	Positive results from OMS201 Phase 1/2 trial in patients undergoing urologic procedures	0	None
2010-12-29	CEL-SCI initiates Multikine Phase III trail for head and neck cancer	0	None
2010-12-29	Merck confirms plans for developing vernakalant drug for atrial fibrillation	0	None
2010-12-28	Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval	0	None
2010-12-28	Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease	0	None
2010-12-28	Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme	0	None
2010-12-28	Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia	0	None
2010-12-27	Emergent initiates AV7909 Phase I trail for Anthrax vaccine	0	None
2010-12-23	Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary	0	None
2010-12-23	Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand	0	None
2010-12-23	Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension	0	None
2010-12-23	Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM	0	None
2010-12-23	Medicago completes first part of H5N1 vaccine Phase II trial	0	None
2010-12-23	Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis	0	None
2010-12-23	Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease	0	None
2010-12-23	Abbott, AstraZeneca discontinue CERTRIAD development collaboration	0	None
2010-12-22	Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer	0	None
2010-12-22	Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder	0	None
2010-12-22	New era for anticoagulant therapy	0	None
2010-12-22	BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients	0	None
2010-12-22	Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV	0	None
2010-12-22	Amorcyte reports AMR-001 phase I trial results in heart attack patients	0	None
2010-12-21	Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease	0	None
2010-12-21	Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia	0	None
2010-12-21	Biovest issues FAQ update on BiovaxID personalized cancer vaccine	0	5
2010-12-21	Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins	0	None
2010-12-21	Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy	0	None
2010-12-21	Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis	0	None
2010-12-20	Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors	0	None
2010-12-20	VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain	0	None
2010-12-20	Bristol-Myers Squibb, Oncolys complete license agreement for festinavir	0	None
2010-12-20	Rexahn granted Japanese patent for preclinical compound RX-0047	0	None
2010-12-20	Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers	0	None
2010-12-20	Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients	0	None
2010-12-20	Fibrocell Science submits response to FDA CR letter for azficel-T BLA	0	None
2010-12-20	Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD	0	None
2010-12-20	Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders	0	None
2010-12-20	Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO	0	1
2010-12-20	Chelsea completes successful NORTHERA pre-NDA assessment with FDA	0	None
2010-12-20	SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development	0	None
2010-12-20	Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction	0	None
2010-12-20	Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM	0	None
2010-12-20	4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients	0	None
2010-12-19	CF patients with normal to mildly impaired lung function may benefit from new investigational drug	0	None
2010-12-17	Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients	0	None
2010-12-17	Catalyst receives $4.0M milestone payment from Pfizer under hemophilia Factor VIIa program	0	None
2010-12-17	MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA	0	None
2010-12-17	NovImmune obtains additional financing of CHF 20 million	0	None
2010-12-17	Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis	0	5
2010-12-17	GSK, Impax enter global development, commercialization agreement for PD investigational product, IPX066	0	None
2010-12-17	FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression	0	None
2010-12-17	Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207	0	None
2010-12-16	FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate	0	None
2010-12-16	Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection	0	None
2010-12-16	Researchers begin placebo-controlled trial to test drug treatment for Rett syndrome	0	None
2010-12-16	Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor	1	None
2010-12-16	Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels	0	None
2010-12-16	BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis	0	None
2010-12-16	CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer	0	None
2010-12-16	ADVENTRX seeks meeting with FDA to discuss ANX-514 docetaxel emulsion study findings	0	None
2010-12-16	Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea	0	None
2010-12-16	HealthLinx's OvPlex performs better over CA125 in part 1 of multinational ovarian cancer biomarker study	0	None
2010-12-16	Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth	0	None
2010-12-16	Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy	0	5
2010-12-15	Clinical Investigation – ground-breaking new launch from Future Science	0	None
2010-12-15	Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma	0	None
2010-12-15	Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer	0	None
2010-12-15	Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study	0	None
2010-12-15	Researchers introduce new class of drugs for HCV patients	0	None
2010-12-15	MHRA issues notice of acceptance for BioMarin's GALNS Phase 3 trial in MPS IVA	0	None
2010-12-15	Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis	0	None
2010-12-15	Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly	0	None
2010-12-15	Myotec, Hybrid merge to form PsiOxus Therapeutics	0	None
2010-12-15	NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer	0	None
2010-12-15	Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010	0	None
2010-12-15	CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model	0	None
2010-12-15	Hemispherx granted extension to modify Ampligen NDA for CFS indication	0	None
2010-12-15	DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients	0	5
2010-12-15	Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors	0	4
2010-12-14	ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis	0	None
2010-12-14	Glycotope receives innovation award 2010 for GlycoExpress technology platform	0	None
2010-12-14	Tolerx commences TRX518 Phase 1 trial in malignant melanoma	0	None
2010-12-14	Provectus commences PH-10 Phase 2c trial for psoriasis	0	None
2010-12-14	VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA	0	None
2010-12-14	Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma	0	None
2010-12-14	Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis	0	None
2010-12-14	Pharmasset initiates dosing in PSI-7977 exploratory study in HCV	0	None
2010-12-14	Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced	0	None
2010-12-14	Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis	0	None
2010-12-14	Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence	0	None
2010-12-14	Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS	0	None
2010-12-14	GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer	0	None
2010-12-14	Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV	0	None
2010-12-14	Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE	0	None
2010-12-14	Drug to reverse immunological decline in aging	0	None
2010-12-14	Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles	0	None
2010-12-14	Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring	0	None
2010-12-14	FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography	0	None
2010-12-13	Lilly suspends tasisulam global Phase III study in metastatic melanoma	0	None
2010-12-13	PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults	0	None
2010-12-13	Intercell to stop further development of Travelers' Diarrhea Vaccine Patch	0	None
2010-12-13	Bionovo reports positive Menerba clinical program meeting with FDA	0	None
2010-12-13	New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism	0	None
2010-12-13	Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer	0	None
2010-12-13	GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR	0	None
2010-12-13	Syndax reports promising results from entinostat preclinical studies in breast cancer	0	None
2010-12-13	Xeloda may reduce recurrence of faster growing breast cancers: Study	0	None
2010-12-13	Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC	0	None
2010-12-13	Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial	0	None
2010-12-13	Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients	0	None
2010-12-13	Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer	0	None
2010-12-10	Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer	0	None
2010-12-10	Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies	0	None
2010-12-10	Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension	0	None
2010-12-10	Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results	0	None
2010-12-10	Nektar's new NKTR-102 Phase 2 data in metastatic breast cancer to be presented at 33rd CTRC-AACR SABCS	0	None
2010-12-10	Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c	0	None
2010-12-10	Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer	0	None
2010-12-10	Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin	0	None
2010-12-10	GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine	0	5
2010-12-10	Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency	0	None
2010-12-10	Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium	0	None
2010-12-10	Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer	0	None
2010-12-10	Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010	0	None
2010-12-09	Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure	0	None
2010-12-09	BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain	0	None
2010-12-09	Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program	0	None
2010-12-09	Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting	0	None
2010-12-09	Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia	0	None
2010-12-09	Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients	0	None
2010-12-09	Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis	0	None
2010-12-09	VIRxSYS presents study results of VRX1116 at HIV DART 2010	0	None
2010-12-09	p53 activation offers a novel strategy for cancer therapy	0	None
2010-12-09	New technique jumpstarts growth of nerve fibers to reverse stroke damage	0	None
2010-12-09	Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting	0	None
2010-12-09	Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010	0	1.5
2010-12-09	Euthymics's EB-1010 effective in treatment of major depressive disorder: Study	0	None
2010-12-09	Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence	0	None
2010-12-08	Bavarian Nordic receives SPA for Phase 3 study of PROSTVAC for advanced prostate cancer	0	4
2010-12-08	Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH	0	None
2010-12-08	Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone	0	None
2010-12-08	AiCuris announces completion of AIC316 Phase II genital herpes trial	0	5
2010-12-08	Novel therapy against hepatitis C disease	0	None
2010-12-08	SEEK reports Phase I safety trail for investigational flu vaccine	0	None
2010-12-08	Three abstracts on Defibrotide presented at ASH Annual Meeting	0	None
2010-12-08	Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial	0	None
2010-12-08	Immunomedics reports CD22 antibody produced significant anti-tumor response	0	None
2010-12-08	Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH	0	None
2010-12-08	GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010	0	None
2010-12-08	FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity	0	None
2010-12-08	QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis	0	5
2010-12-08	FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa	0	None
2010-12-07	Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma	0	None
2010-12-07	Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL	0	5
2010-12-07	John Theurer Cancer Center presents research findings at ASH meeting	0	None
2010-12-07	Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010	0	None
2010-12-07	Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer	0	None
2010-12-07	Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma	0	None
2010-12-07	Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma	0	None
2010-12-07	Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients	0	None
2010-12-07	Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH	0	None
2010-12-07	Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients	0	None
2010-12-07	Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology	0	None
2010-12-07	Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma	0	None
2010-12-07	Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial	0	None
2010-12-07	Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH	0	None
2010-12-07	IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study	0	None
2010-12-07	Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma	0	None
2010-12-07	Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk	0	None
2010-12-07	Global phase III study to provide novel extended release of topiramate	0	None
2010-12-07	Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis	0	5
2010-12-07	Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH	0	None
2010-12-07	Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting	0	None
2010-12-07	rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data	0	5
2010-12-07	New drug appears to help patients with chronic myeloid leukemia	0	None
2010-12-07	Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia	0	None
2010-12-07	Sequella files SQ109 IND for Phase 2 studies in H. pylori-related duodenal ulcers	0	None
2010-12-07	New analysis of Soliris in patients with PNH presented at ASH Annual Meeting	0	5
2010-12-07	FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA	0	None
2010-12-07	VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction	0	None
2010-12-07	GeoVax expands Phase 2a clinical trial for MVA62B HIV/AIDS vaccine	0	None
2010-12-07	No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial	0	None
2010-12-07	ArQule initiates enrollment in ARQ 736 Phase 1 clinical trial for advanced solid tumors	0	None
2010-12-06	Achillion Pharmaceuticals to present clinical study data of ACH-1625 at APASL 2011	0	5
2010-12-06	Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010	0	None
2010-12-06	Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine	0	None
2010-12-06	Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL	0	None
2010-12-06	Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS	0	None
2010-12-06	Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH	0	None
2010-12-06	Genentech announces Phase II study results of RG1678 for treatment of schizophrenia	0	None
2010-12-06	New research focusing on VTE presented at ASH Annual Meeting	0	None
2010-12-06	Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma	0	None
2010-12-06	Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting	0	None
2010-12-06	Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010	0	None
2010-12-06	Cell Therapeutics announces new pixantrone EOS follow up results	0	5
2010-12-06	Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma	0	None
2010-12-06	Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010	0	5
2010-12-06	Immunomedics reports results of milatuzumab-based combination treatments for NHL patients	0	None
2010-12-06	Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases	0	None
2010-12-06	BioCryst reports Phase 2 trial data of forodesine in patients with CLL	0	None
2010-12-06	Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010	0	None
2010-12-06	Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody	0	None
2010-12-06	Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010	0	None
2010-12-06	Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression	0	4.5
2010-12-06	Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting	0	None
2010-12-06	Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS	0	None
2010-12-06	Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting	0	None
2010-12-06	Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting	0	None
2010-12-06	Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH	0	None
2010-12-06	Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting	0	5
2010-12-05	QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study	0	None
2010-12-04	Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition	0	None
2010-12-04	Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease	0	None
2010-12-04	Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A	0	3
2010-12-04	Pfizer plans regulatory submissions of bosutinib for CML based on BELA study	0	None
2010-12-04	Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010	0	None
2010-12-04	Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting	0	None
2010-12-04	Mitoxantrone increases survival for children with relapsed ALL, trial results show	0	None
2010-12-04	Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study	0	None
2010-12-04	FDA extends PDUFA review target date for BENLYSTA BLA to treat systemic lupus erythematosus	0	None
2010-12-04	Phase III studies should make meaningful difference in patients' quality of life: Commentary	0	None
2010-12-03	SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting	0	None
2010-12-03	Arthritis drug reduces incidence of non-melanoma skin cancers	0	None
2010-12-03	MHRA issues notice of acceptance for BioMarin's BMN 673 for genetically-defined cancers	0	None
2010-12-03	FDA accepts IND application to initiate human clinical trial to evaluate BNC	0	None
2010-12-03	Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics	0	None
2010-12-03	Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer	0	None
2010-12-02	Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL	0	None
2010-12-02	Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting	0	None
2010-12-02	Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes	0	None
2010-12-02	AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium	0	None
2010-12-02	Shire reports topline results from FAST-3 Firazyr Phase III trials for acute attacks of hereditary angioedema	0	None
2010-12-02	Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting	0	None
2010-12-02	Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders	0	None
2010-12-02	CytRx commences tamibarotene Phase 2b clinical trial in NSCLC	0	None
2010-12-02	Wake Forest University to begin clinical trial for low-grade gliomas	0	None
2010-12-02	Daiichi Sankyo completes patient enrollment in Phase III edoxaban study for AF	0	None
2010-12-02	Oncolytics initiates enrollment in Phase II ovarian cancer study	0	5
2010-12-02	Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes	0	None
2010-12-02	Tolerx enters collaborative research agreement with Cancer Research Institute	0	None
2010-12-01	Pfizer to present data on hematology portfolio at ASH Annual Meeting	0	None
2010-12-01	SPARTAC study examines ways to limit immune system damage in HIV infection	0	5
2010-12-01	Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH	0	None
2010-12-01	Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial	0	None
2010-12-01	Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting	0	None
2010-12-01	New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease	0	None
2010-12-01	Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting	0	None
2010-12-01	Rush University enrolls first U.S. patient in international clinical trial for melanoma	0	None
2010-12-01	Array BioPharma achieves $10 million clinical research milestone in Celgene collaboration	0	None
2010-12-01	GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center	0	None
2010-12-01	PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes	0	None
2010-12-01	Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors	0	None
2010-11-30	NSAID Celebrex may help prevent non-melanoma skin cancer development: Research	0	None
2010-11-30	Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients	0	None
2010-11-30	Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1	0	None
2010-11-30	Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV	0	None
2010-11-30	FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA	0	None
2010-11-30	Neuraltus reports positive results from NP001 Phase 1 study for ALS	0	1.8
2010-11-30	Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma	0	None
2010-11-30	Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain	0	None
2010-11-30	Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia	0	4.5
2010-11-30	Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia	0	None
2010-11-30	Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV	0	None
2010-11-30	ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients	0	None
2010-11-30	Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML	0	None
2010-11-30	ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting	0	None
2010-11-30	DATATRAK applauds Cosmo Pharmaceuticals for positive top-line results from budesonide MMX	0	None
2010-11-30	FG-2216 drug offers new treatment option for kidney disease-related anemia	0	None
2010-11-30	GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine	0	None
2010-11-30	Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention	0	None
2010-11-30	Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation	0	None
2010-11-30	NIAID scientists confirm antiviral activity of two lead compounds against HPV	1	5
2010-11-30	Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer	0	None
2010-11-30	Array BioPharma to present data on ARRY-520 Phase 1 trial for multiple myeloma at ASH Annual Meeting	0	None
2010-11-30	Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting	0	None
2010-11-30	Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting	0	None
2010-11-29	Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting	0	None
2010-11-29	FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres	0	None
2010-11-29	Merck announces initial results from ISENTRESS Phase III study in HIV-1	0	None
2010-11-29	Hemispherx requests FDA time extension for Ampligen NDA data resubmission	0	None
2010-11-29	Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer	0	None
2010-11-29	Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides	0	None
2010-11-25	Phase 3 trial: TYSABRI improves vision in MS patients	0	None
2010-11-25	Neptune, Acasti completes preclinical program comparing CaPre with Lovaza	0	None
2010-11-25	Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients	0	None
2010-11-25	Glycotex receives cash grant under QTDP program to develop GLYC-101 Gel	0	None
2010-11-24	Advaxis initiates ADXS11-001 clinical trial for cervix cancer	0	None
2010-11-24	A new treatment landscape for triple-negative breast cancer	0	None
2010-11-24	FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study	0	None
2010-11-24	GCM supports iPrEx Study to prevent HIV infection among MSM	0	None
2010-11-24	Important queries about PrEP, iPrEx trial for HIV infection	0	None
2010-11-24	HIV treatment drugs also help prevent HIV infection in high-risk men: Study	1	None
2010-11-24	iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men	0	None
2010-11-24	iPrEx trial shows reduction in new HIV infections	0	None
2010-11-24	Provectus reports progress in PV-10 program for metastatic melanoma	0	None
2010-11-24	iPrEx oral PrEP study achieves major milestone in HIV prevention research	0	None
2010-11-24	CONRAD congratulates Global iPrEx study team for HIV prevention trial	0	None
2010-11-24	XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies	0	None
2010-11-23	ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone	0	None
2010-11-23	CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer	0	5
2010-11-23	DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns	0	None
2010-11-23	Compugen announces development of Protein Family Members Discovery Platform	0	None
2010-11-23	Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication	0	None
2010-11-23	Hemispherx announces publication of Ampligen Phase III data in Journal of Applied Research	0	None
2010-11-23	Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program	0	None
2010-11-23	BioCancell raises $5.1 million by excess demand in public offering	0	None
2010-11-22	Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference	0	None
2010-11-22	Stem cell trial for eye disease receives FDA approval	2	4.7
2010-11-22	Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides	0	5
2010-11-22	Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis	0	None
2010-11-22	FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD	0	None
2010-11-22	Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease	0	None
2010-11-22	S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies	0	None
2010-11-22	Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy	0	None
2010-11-22	Acthar Gel may be a viable treatment option for resistant nephrotic syndrome	0	None
2010-11-22	Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions	0	None
2010-11-22	Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas	0	None
2010-11-22	VYTORIN reduces major vascular events in patients with chronic kidney disease	1	3.5
2010-11-22	Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD	0	None
2010-11-22	SHARP study shows cholesterol-lowering effective for patients with kidney disease	0	None
2010-11-22	Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function	0	None
2010-11-21	Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints	0	None
2010-11-21	Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting	0	None
2010-11-20	Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting	0	None
2010-11-20	Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting	0	None
2010-11-20	Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting	0	None
2010-11-20	Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint	0	None
2010-11-20	VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies	0	None
2010-11-20	Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium	0	None
2010-11-19	Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix	0	None
2010-11-19	FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia	0	None
2010-11-19	Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting	0	None
2010-11-19	AVEO's RON antibody shows anti-tumor activity in human cancer xenografts	0	None
2010-11-19	ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium	0	None
2010-11-19	ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium	0	None
2010-11-19	Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium	0	None
2010-11-19	ACE-041 drug may provide new option to treat cancer	0	None
2010-11-19	DoD recommends funding for Synta's STA-9584 for prostate cancer study	0	None
2010-11-19	Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS	0	1
2010-11-19	GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events	0	None
2010-11-19	AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers	0	None
2010-11-19	COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors	0	None
2010-11-19	Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium	0	None
2010-11-19	OXiGENE updates data on FALCON trial for non-small cell lung cancer	0	None
2010-11-19	YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites	0	None
2010-11-19	Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure	0	None
2010-11-19	Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A	0	None
2010-11-19	Spectrum to present four key belinostat data for solid cancers at ASH annual meeting	0	None
2010-11-19	Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease	0	2
2010-11-19	Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York	0	None
2010-11-19	Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium	0	None
2010-11-19	Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium	0	None
2010-11-18	Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium	0	None
2010-11-18	Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy	0	None
2010-11-18	Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine	0	None
2010-11-18	Researchers report results from Phase III DEFINE study for coronary heart disease	0	5
2010-11-18	Access Pharmaceuticals to present two oncology posters at CPR Conference	0	None
2010-11-18	Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C	0	None
2010-11-18	MK-4827 drug candidate shows promising anti-tumour activity in first human trial	0	None
2010-11-18	Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer	0	3
2010-11-18	Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer	0	5
2010-11-18	Inovio achieves positive results in Phase I PENNVAX-B study for HIV	0	None
2010-11-18	Clinical trial shows dalfampridine tablets improve walking ability in MS patients	0	None
2010-11-18	Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression	0	None
2010-11-18	Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium	0	None
2010-11-18	Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo	0	None
2010-11-18	Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association	0	None
2010-11-18	Regado presents poster on REG3 at AHA Scientific Sessions meeting	0	None
2010-11-18	VX-770 drug candidate improves lung function in people with cystic fibrosis	0	None
2010-11-18	Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting	0	None
2010-11-17	Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting	0	None
2010-11-17	New investigational drug improves lung function in CF patients	0	None
2010-11-17	Scientists investigate new class of drugs for treating kidney failure	0	None
2010-11-17	Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium	0	None
2010-11-17	Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure	0	None
2010-11-17	MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.	0	None
2010-11-17	Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer	0	None
2010-11-17	Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference	0	None
2010-11-17	EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors	0	None
2010-11-17	Anthera places voluntary hold on A-623 Phase 2b study for lupus	0	None
2010-11-17	Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications	0	None
2010-11-17	Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer	0	None
2010-11-17	Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium	0	None
2010-11-17	TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients	0	None
2010-11-17	Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study	0	None
2010-11-17	JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes	0	None
2010-11-17	UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds	0	None
2010-11-17	AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors	0	None
2010-11-17	ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases	0	None
2010-11-17	Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan	0	None
2010-11-16	Stem cells for stroke: Clinical trial commences	0	5
2010-11-16	Anti-stroke blood thinner shows promise in large clinical trials	0	None
2010-11-16	Diuretic lessens risk of death from mild heart failure: Study	0	None
2010-11-16	4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium	0	None
2010-11-16	Merrion prepares Phase III study for Orazol in breast cancer treatment	0	None
2010-11-16	BiovaxID lymphoma vaccine to be featured at ASH Meeting	0	None
2010-11-16	St. Jude presents results from ASSERT trial for stroke at American Heart Association	0	None
2010-11-16	Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association	0	4
2010-11-16	Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer	0	None
2010-11-16	Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association	0	None
2010-11-16	PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association	0	5
2010-11-16	ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting	0	None
2010-11-16	Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association	0	None
2010-11-16	Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda	0	None
2010-11-15	Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting	0	None
2010-11-15	Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting	0	5
2010-11-15	New investigational drug is well tolerated in children with nmCF	0	None
2010-11-15	Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients	0	None
2010-11-15	Novel heart attack treatment results presented at premier USA cardiology forum	0	None
2010-11-15	No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia	0	None
2010-11-15	SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium	0	None
2010-11-15	Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal	0	None
2010-11-15	Scios announces results of ASCEND-HF trial for ADHF treatment	0	None
2010-11-15	Inovio third quarter total revenue decreases from $3.6 million to $1.3 million	0	None
2010-11-15	POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session	0	None
2010-11-15	Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB	0	None
2010-11-15	Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda	0	None
2010-11-15	Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting	0	None
2010-11-12	Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting	0	1
2010-11-12	Nile third quarter net loss decreases to $1.8 million	0	None
2010-11-12	Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000	0	None
2010-11-12	Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session	0	None
2010-11-12	Inovio to update HVTN 080 Phase I clinical study for HIV at HVTN Conference	0	None
2010-11-12	Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference	0	None
2010-11-12	Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate	0	None
2010-11-12	Advaxis receives $244,479 QTDP credit for ADXS11-001 trial	0	None
2010-11-12	NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010	0	None
2010-11-11	SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors	0	None
2010-11-11	NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients	0	None
2010-11-11	Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis	0	None
2010-11-11	Study investigates long-term outcome of REYATAZ/ritonavir regimens in ARV-experienced patients	0	None
2010-11-11	Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting	0	None
2010-11-11	4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million	0	None
2010-11-11	Cyclacel announces publication of sapacitabine in British Journal of Cancer	0	None
2010-11-11	Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium	0	None
2010-11-11	Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies	0	None
2010-11-11	Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C	0	None
2010-11-11	Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility	0	None
2010-11-11	Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium	0	None
2010-11-11	Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment	0	None
2010-11-11	Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia	0	None
2010-11-11	Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints	1	None
2010-11-10	Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV	0	None
2010-11-10	Amarin reports $31.4 million cash balance for third quarter 2010	0	None
2010-11-10	Positive results from XOMA 052 study in patients with uveitis of Behcet's disease	0	5
2010-11-10	Zalicus third quarter total revenue decreases to $1.2 million	0	None
2010-11-10	Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting	0	None
2010-11-10	Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR	0	2
2010-11-10	TRU-016 abstracts to be presented at ASH meeting	0	None
2010-11-10	Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting	0	5
2010-11-10	Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study	0	None
2010-11-10	Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation	0	None
2010-11-10	BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease	0	None
2010-11-10	TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome	0	None
2010-11-10	Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation	0	None
2010-11-10	Diamyd completes patient screening for DiaPrevent Phase III study	0	None
2010-11-10	New York Times examines HIV prevention products undergoing clinical trials	0	None
2010-11-10	Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction	0	None
2010-11-09	Phytomedics awarded $244,000 QTDP grant for development of RA drug	0	None
2010-11-09	NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults	0	None
2010-11-09	EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010	0	None
2010-11-09	Discovery Labs reports net operating loss of $6.2 million for third quarter 2010	0	None
2010-11-09	Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics	0	None
2010-11-09	Arena third quarter net loss increases to $36.3 million	0	None
2010-11-09	ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA	0	None
2010-11-09	ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs	0	None
2010-11-09	Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting	0	5
2010-11-09	Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products	0	None
2010-11-09	EVP-6124 receptor acts as co-agonist with ACh to enhance cognition	0	None
2010-11-09	Colcrys safe for treating gout flares	0	None
2010-11-09	Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer	0	None
2010-11-09	SIMPONI injection improves inflammation, structural damage in RA patients	0	None
2010-11-09	Merrimack receives $2.44 million under QTDP program to support cancer research	0	None
2010-11-09	Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack	0	None
2010-11-09	EpiCept third quarter net loss decreases to $3.2 million	0	None
2010-11-09	BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting	0	None
2010-11-09	Omthera initiates ECLIPSE study for treatment of high triglycerides	0	None
2010-11-09	New data on Soliris for PNH treatment to be presented at ASH Annual Meeting	0	None
2010-11-08	Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study	0	None
2010-11-08	NUVO announces positive results from WF10 Phase 2 clinical trial for severe allergic rhinitis	0	None
2010-11-08	Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease	0	None
2010-11-08	Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout	0	None
2010-11-08	TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB	0	None
2010-11-08	MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine	0	None
2010-11-08	TransTech Pharma, High Point receive $1.96 million grants under QTDP program	0	None
2010-11-08	Santarus's budesonide MMX drug shows positive result for active ulcerative colitis	0	None
2010-11-08	bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction	0	5
2010-11-08	Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma	0	None
2010-11-08	Pervasis receives $920,000 in grants under QTDP program	0	None
2010-11-08	Synergy receives $244,479 grant under QTDP program to develop plecanatide for gastrointestinal disorders	0	None
2010-11-08	SGN-35 drug reduces tumor growth in Hodgkin's lymphoma	0	None
2010-11-08	Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting	0	None
2010-11-08	Inviragen to present data on CHIKV vaccine at ASTMH meeting	0	None
2010-11-08	ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis	0	None
2010-11-08	Sanofi Pasteur's dengue vaccine enters phase III trial in Australia	0	None
2010-11-08	Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors	0	None
2010-11-08	Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress	0	None
2010-11-08	Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R	0	None
2010-11-08	New malaria drug can save millions of lives: Study	0	None
2010-11-07	AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress	0	5
2010-11-07	Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program	0	None
2010-11-04	Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009	0	None
2010-11-04	NWBT receives $490,000 in two grants under QTDP program	0	None
2010-11-04	Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs	0	None
2010-11-04	AVEO third quarter total collaboration revenues increase to $6.2 million	0	None
2010-11-04	Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence	0	None
2010-11-04	NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting	0	None
2010-11-04	New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data	0	5
2010-11-04	4SC's vidofludimus Phase IIa study in IBD meets primary endpoint	0	None
2010-11-04	Phase III study suggests CYCLOSET tablets improve glycemic control	0	None
2010-11-04	World's most clinically advanced dengue vaccine candidate enters first phase 3 clinical study	0	5
2010-11-04	Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer	0	5
2010-11-04	Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial	0	None
2010-11-04	Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases	0	None
2010-11-04	Coronado completes series of private financings	0	None
2010-11-04	Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants	0	None
2010-11-04	Afinitor tablets decrease size of SEGA associated with tuberous sclerosis	0	None
2010-11-04	Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis	0	None
2010-11-04	New antibody with SGN-35 drug produces remission in Hodgkin lymphoma	0	3.5
2010-11-04	Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction	0	None
2010-11-04	Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program	0	None
2010-11-04	Aeolus receives $489,000 grant under QTDP program for two lead compounds	0	None
2010-11-04	Bristol-Myers Squibb and Simcere partner to co-develop oncology compound	0	None
2010-11-04	Biogen Idec and Cardiokine terminate lixivaptan collaboration	0	None
2010-11-04	PolyMedix receives $488,958 grants under QTDP program	0	None
2010-11-04	Alnylam third quarter revenue increases from $24.2 million to $27.7 million	0	None
2010-11-03	Bortezomib reduces inflammation and promotes bone healing in arthritis models	0	None
2010-11-03	QLT third quarter sales decreases 12.9% to $20.5 million	0	None
2010-11-03	Incyte announces achievement of $50 million in INCB18424 clinical trial	0	None
2010-11-03	SYMBICORT improves lung function in African American asthma patients compared to budesonide alone	0	4
2010-11-03	Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis	0	None
2010-11-03	GenVec receives $244,479 grant under QTDP program	0	None
2010-11-03	Celsion receives $244,000 grant under QTDP program	0	None
2010-11-03	POZEN’s therapeutic development programs qualified to receive federal grant under PPACA	0	None
2010-11-03	Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study	0	None
2010-11-03	BioCryst receives $1.1 million in grants under QTDP program	0	None
2010-11-03	Immunomedics product candidates, technologies receive recognition from QTDP program	0	None
2010-11-03	Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting	0	None
2010-11-03	Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program	0	None
2010-11-03	ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium	0	None
2010-11-03	Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint	0	None
2010-11-03	BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer	0	5
2010-11-03	Bristol-Myers extends time to review BLA for ipilimumab in melanoma	0	None
2010-11-03	NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia	0	5
2010-11-03	CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program	0	None
2010-11-03	Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients	0	None
2010-11-03	Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C	0	3.5
2010-11-02	Asthmatx presents 2-year results from AIR2 Trial of bronchial thermoplasty in severe asthma	0	None
2010-11-02	NPS third quarter net loss increases to $15.7 million	0	None
2010-11-02	RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome	0	None
2010-11-02	Inhibitex to present INX-189 data for HCV infections at AASLD Meeting	0	None
2010-11-02	TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors	0	None
2010-11-02	Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial	0	None
2010-11-02	Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease	0	None
2010-11-02	ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection	0	None
2010-11-02	Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1	0	None
2010-11-02	BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer	0	None
2010-11-02	EMA issues Scientific Advice to Genta's clinical development plan for tesetaxel in patients with gastric cancer	0	None
2010-11-02	PPACA program provides $733,438 grant to Inovio	0	1
2010-11-02	Positive results from linaclotide Phase 3 trial in patients with IBS-C	0	None
2010-11-01	Telbivudine prevents HBV transmission from mothers to newborns: Study	0	None
2010-11-01	Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment	0	None
2010-11-01	GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer	0	None
2010-11-01	Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection	0	None
2010-11-01	Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine	0	None
2010-11-01	Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium	0	None
2010-11-01	FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension	0	5
2010-11-01	Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection	0	5
2010-11-01	Catalyst’s CPP-115 improves retinal safety profile than vigabatrin	0	None
2010-11-01	Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C	0	None
2010-11-01	Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain	0	None
2010-11-01	Shield signs strategic commercialization agreement for ST10-021 iron therapy product	0	None
2010-11-01	Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV	0	None
2010-11-01	Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection	0	None
2010-11-01	Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting	0	None
2010-11-01	NeurAxon’s NXN-188 compound effective for acute migraine treatment	0	None
2010-11-01	Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting	0	None
2010-11-01	Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting	0	3
2010-11-01	Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting	0	None
2010-11-01	Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010	0	3
2010-11-01	Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010	0	None
2010-11-01	Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting	0	None
2010-10-30	OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International	0	None
2010-10-30	Presidio to present PPI-461 data for HCV infection at AASLD meeting	0	None
2010-10-30	CONCERTA improves handwriting performance in children with ADHD: Study	0	None
2010-10-30	Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne	0	None
2010-10-30	Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting	0	None
2010-10-30	Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting	0	None
2010-10-30	AVEO to raise $61 million through private placement	0	None
2010-10-30	OHSU to lead next phase of HuCNS-SC trial for NCL in children	0	None
2010-10-29	Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne	0	None
2010-10-29	MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress	0	None
2010-10-29	GSK and Amicus announce Amigal development and commercialization agreement	0	None
2010-10-29	Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder	0	1
2010-10-29	57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study	0	None
2010-10-29	ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine	0	None
2010-10-29	Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms	0	None
2010-10-29	Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD	0	None
2010-10-29	StemCells initiates HuCNS-SC second clinical trial for Batten disease in children	0	None
2010-10-29	Geron 2010 third quarter revenue increases from $494,000 to $546,000	0	None
2010-10-29	ImmunoGen first quarter net loss increases to $12.9 million	0	None
2010-10-29	Amira initiates AM152 Phase 1 clinical study for fibrotic diseases	0	None
2010-10-28	Antigenics third quarter net loss decreases from $10.8 million to $5.9 million	0	None
2010-10-28	Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment	0	None
2010-10-28	QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa	0	4
2010-10-28	Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A	0	None
2010-10-28	Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine	0	2.5
2010-10-28	Curemark adds two sites in California for CM-AT Phase III clinical trial program	0	None
2010-10-28	Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3	0	None
2010-10-28	Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW	0	3
2010-10-28	Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China	0	None
2010-10-28	ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients	0	None
2010-10-28	EpiCept, FDA reach agreement on regulatory path forward for Ceplene	0	None
2010-10-28	Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia	0	5
2010-10-28	New oral drug shrinks IMT sarcoma driven by abnormally activated protein	0	None
2010-10-28	BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA	0	None
2010-10-28	Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials	0	None
2010-10-27	Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium	0	5
2010-10-27	Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease	0	None
2010-10-27	MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients	0	None
2010-10-27	Decision Resources reduces global sales forecast for tanezumab by $1.2 billion	0	None
2010-10-27	Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda	0	None
2010-10-27	Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain	0	None
2010-10-26	Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia	0	None
2010-10-26	Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program	0	None
2010-10-26	Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM	0	None
2010-10-26	TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment	0	None
2010-10-26	Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange	0	None
2010-10-26	Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium	0	None
2010-10-26	Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL	0	None
2010-10-26	Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome	0	None
2010-10-26	Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta	0	None
2010-10-26	Trius receives patent protection for torezolid phosphate in the U.S.	0	None
2010-10-26	TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium	0	None
2010-10-26	Chemoradiotherapy can reduce bladder cancer recurrence	0	None
2010-10-26	ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer	0	5
2010-10-26	LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting	0	None
2010-10-26	Dual antiplatelet therapy study expanded into Australia and New Zealand	0	None
2010-10-26	Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting	0	None
2010-10-26	Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV	0	None
2010-10-25	Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone	0	None
2010-10-25	Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia	0	None
2010-10-25	Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction	0	None
2010-10-25	Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze	0	None
2010-10-25	Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium	0	None
2010-10-25	Soligenix reports Phase 2 clinical trial results of orBec for GVHD	0	None
2010-10-25	NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting	0	None
2010-10-25	Antigenics expands HSPPC-96 Phase 2 clinical study in glioma	0	None
2010-10-25	Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint	0	None
2010-10-25	Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting	0	None
2010-10-25	Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis	0	None
2010-10-25	Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting	0	None
2010-10-25	Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis	0	None
2010-10-25	Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting	0	None
2010-10-22	Astellas suspends patient enrollment from ACT 5 study of KYNAPID	0	None
2010-10-22	Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference	0	3
2010-10-22	Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal	0	None
2010-10-22	Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients	0	5
2010-10-22	TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection	0	None
2010-10-22	AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease	0	None
2010-10-22	Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM	0	None
2010-10-22	Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories	0	5
2010-10-22	Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease	0	None
2010-10-22	Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia	0	None
2010-10-21	Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients	0	None
2010-10-21	Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study	0	None
2010-10-21	PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology	0	None
2010-10-21	BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting	0	None
2010-10-21	ISCTM to develop solutions for CNS clinical trial methodology	0	None
2010-10-21	OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS	0	None
2010-10-21	Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV	0	None
2010-10-21	MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress	0	None
2010-10-21	Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection	0	None
2010-10-21	Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer	0	None
2010-10-21	Aastrom submits SPA for Phase 3 clinical development program in critical limb ischemia to FDA	0	5
2010-10-21	DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy	0	None
2010-10-21	Genzyme third quarter revenue increases to $1.0 billion	0	None
2010-10-21	Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment	0	5
2010-10-21	Genzyme reports results of Clolar combination Phase 3 trial in adult AML	0	None
2010-10-21	IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer	0	None
2010-10-20	Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy	0	5
2010-10-20	Initiation of INCB28050 Phase IIb trial triggers $19M milestone payment from Eli Lilly to Incyte	0	None
2010-10-20	Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate	0	None
2010-10-20	Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study	0	None
2010-10-20	European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia	0	None
2010-10-20	LANL's researcher to implement first human trial of mosaic HIV vaccine candidate	0	None
2010-10-20	Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS	0	None
2010-10-20	NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance	0	None
2010-10-20	MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma	0	None
2010-10-20	Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease	0	None
2010-10-19	BioMarin announces BMN-111 program for treatment of achondroplasia	0	4
2010-10-19	Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data	0	None
2010-10-19	Acorda announces data of GGF2 preclinical studies for focal ischemic stroke	0	None
2010-10-19	Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC	0	None
2010-10-19	Cytheris initiates ORVACS Phase II clinical trial to study HIV infection	0	None
2010-10-19	Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC	0	None
2010-10-19	Positive results from Diamyd Medical's NP2 Enkephalin Phase I trial for chronic pain	0	5
2010-10-19	Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis	0	None
2010-10-19	Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis	0	None
2010-10-19	New research coalition to design first human trial of mosaic HIV vaccine candidate	0	None
2010-10-19	Transcept announces Intermezzo tablet preliminary data for insomnia	0	None
2010-10-19	Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting	0	None
2010-10-19	New clinical trial to treat brain cancer launched	0	None
2010-10-19	UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting	0	None
2010-10-18	Groundbreaking melanoma clinical trial initiated by Patrys	0	None
2010-10-18	BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease	0	None
2010-10-18	Studies explore impact of upper GI conditions on sleep	0	None
2010-10-18	Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA	0	None
2010-10-18	Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis	0	None
2010-10-18	Fluticasone gets rid of eosinophils in the esophagus, but does not improve symptoms	1	3
2010-10-18	Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders	0	None
2010-10-18	FDA grants fast track designation for Aastrom's CLI cell therapy development program	0	None
2010-10-18	14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010	0	None
2010-10-18	BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study	0	None
2010-10-18	EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis	0	None
2010-10-18	Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment	0	None
2010-10-18	Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium	0	None
2010-10-18	Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting	0	None
2010-10-18	Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver	0	5
2010-10-18	Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting	0	None
2010-10-18	PTC announces ataluren Phase 2b efficacy data at International Congress	0	None
2010-10-18	Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis	0	None
2010-10-18	Teva Pharmaceutical announces new data from PreCISe study	0	None
2010-10-15	Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress	0	3
2010-10-15	EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma	0	None
2010-10-15	NovaDel announces encouraging data from pilot PK study comparing Duromist to Viagra	0	None
2010-10-15	Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study	0	None
2010-10-15	Oseltamivir reduces mortality in influenza A/H5N1 patients	0	None
2010-10-15	Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients	0	None
2010-10-15	NovaBay to present two poster presentations at IDSA Annual Meeting	0	None
2010-10-15	Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress	0	5
2010-10-15	Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference	0	None
2010-10-15	Knopp Neurosciences forms new parent entity	0	5
2010-10-15	Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment	0	None
2010-10-15	Journal of Clinical Oncology publishes IPI-504 Phase 2 study results	0	None
2010-10-15	Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis	0	None
2010-10-15	FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis	0	5
2010-10-15	Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial	0	None
2010-10-14	Omeros receives additional NIDA grant for clinical studies in Addiction program	0	None
2010-10-14	Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress	0	4
2010-10-14	Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer	0	5
2010-10-14	Acceleron announces ACE-031 Phase 1b study results	0	None
2010-10-14	XenoPort to present XP23829 preclinical data at ECTRIMS meeting	0	None
2010-10-13	Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD	0	None
2010-10-13	Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer	0	None
2010-10-13	Threshold announces TH-302 Phase 1/2 clinical trial interim results	0	None
2010-10-13	JAMA publishes Probuphine Phase 3 clinical trial data	0	None
2010-10-13	Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug	0	None
2010-10-13	Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain	0	None
2010-10-13	Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment	0	None
2010-10-13	CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer	0	None
2010-10-13	MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV	0	None
2010-10-13	US Oncology enrolls 1,000th patient in Phase I clinical trial	0	None
2010-10-13	HSV1716 clinical trial for childhood cancer receives FDA grant	0	None
2010-10-13	Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer	0	None
2010-10-12	USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth	0	None
2010-10-12	Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting	0	None
2010-10-12	First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for advanced breast cancer	0	None
2010-10-12	Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation	0	None
2010-10-12	Helix completes GLP toxicology study milestone in L-DOS47 development program	0	None
2010-10-12	UCB, Synosia Therapeutics announce new strategic partnership in neurology	0	None
2010-10-12	Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points	0	None
2010-10-12	Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors	0	4
2010-10-11	Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds	0	None
2010-10-11	Access highlights clinical benefits of MuGard at ESMO conference	0	None
2010-10-11	Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer	0	None
2010-10-11	Abbott presents data from 4 briakinumab pivotal studies in psoriasis	0	None
2010-10-11	Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO	0	None
2010-10-11	COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate	0	None
2010-10-11	ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC	0	None
2010-10-11	Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis	0	4.5
2010-10-11	Genentech initiates GDC-0449 Phase II clinical trial in BCC patients	0	None
2010-10-11	Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer	0	None
2010-10-11	AVEO presents tivozanib Phase 2 study results at ESMO Congress	0	None
2010-10-11	Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury	0	None
2010-10-11	ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer	0	None
2010-10-11	Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting	0	None
2010-10-11	ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting	0	None
2010-10-11	Allos announces favorable survival data from FOLOTYN Phase 2b study	0	None
2010-10-11	MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial	0	None
2010-10-11	BioSante presents update on LibiGel clinical study at NAMS Annual Meeting	0	None
2010-10-11	OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress	0	5
2010-10-11	Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors	1	None
2010-10-11	Combination of MET and erlotinib delays lung cancer progression: Study	0	None
2010-10-11	Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference	0	None
2010-10-11	Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial	0	None
2010-10-11	Seattle Genetics reports SGN-75 phase I clinical trial data	0	None
2010-10-11	Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease	1	2
2010-10-11	BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study	0	None
2010-10-11	Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer	0	None
2010-10-11	First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer	0	None
2010-10-11	Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors	0	None
2010-10-11	Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research	0	5
2010-10-08	Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints	0	None
2010-10-08	Abiraterone Phase III clinical data to be presented at ESMO meeting	0	5
2010-10-08	Roskamp to initiate RCP-006 clinical trials for Alzheimer's disease	1	5
2010-10-08	Pfizer announces tasocitinib Phase 2 data for plaque psoriasis	0	None
2010-10-08	StemCells provides update on PMD Phase I clinical trial	0	None
2010-10-08	Innovative trial designs may improve efficiency of clinical trials	0	None
2010-10-08	VentiRx announces VTX-1463 trial results for allergic rhinitis treatment	0	None
2010-10-08	Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels	0	None
2010-10-08	Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD	0	None
2010-10-07	Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress	0	None
2010-10-07	Vivaglobin therapy effective for patients with primary immunodeficiency	0	None
2010-10-07	Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting	0	None
2010-10-07	Integra to present multi-center study of peripheral nerve repair at Mexico joint meeting	0	None
2010-10-07	Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study	0	None
2010-10-07	Hizentra therapy effective for primary immunodeficiency patients	0	None
2010-10-07	Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers	0	4
2010-10-07	Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB	0	None
2010-10-07	Neoprobe completes pre-NDA assessment for Lymphoseek with FDA	0	None
2010-10-06	Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress	0	None
2010-10-06	Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID	0	None
2010-10-06	ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray	0	None
2010-10-06	Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation	0	None
2010-10-06	Adeona completes enrollment in Part 2 CopperProof-2 clinical study	0	None
2010-10-06	Innovacell invests 10 million Euros for clinical development	0	None
2010-10-06	Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects	0	None
2010-10-06	Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD	0	None
2010-10-06	Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement	0	None
2010-10-06	Rochester General Hospital Research Institute awarded $7M for Prevnar 13 study of ear infections in children	0	None
2010-10-06	IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial	0	None
2010-10-06	Lixte, NCI collaborate for clinical evaluation of LB-100 compound	0	None
2010-10-05	Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza	0	None
2010-10-05	ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain	0	None
2010-10-05	Archimedes publishes FPNS clinical study results in Pain journal	0	None
2010-10-05	Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research	0	None
2010-10-05	ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit	0	None
2010-10-05	Neuraltus achieves last patient out for NP001, NP002 studies	0	4
2010-10-05	Merck Serono to present Erbitux data at ESMO Congress	0	None
2010-10-05	BioSante to present LibiGel clinical trial update at NAMS Annual Meeting	0	None
2010-10-05	Amgen announces PRIME '203' and '181' Phase 3 trial results	0	None
2010-10-05	Seattle Genetics to present SGN-75 phase I data at ESMO Congress	0	None
2010-10-05	CrystalGenomics to present Phase I MAD study data at Arrowhead Summit	0	5
2010-10-05	Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting	0	None
2010-10-05	Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial	0	None
2010-10-04	Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis	0	None
2010-10-04	Onconova enters agreement with FDA for Estybon Phase 3 trial SPA	0	5
2010-10-04	Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD	1	None
2010-10-04	Neupro improves quality of life in Parkinson's disease patients	0	None
2010-10-04	AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium	0	None
2010-10-04	Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article	0	5
2010-10-04	Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium	0	None
2010-10-03	Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium	0	None
2010-10-03	Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting	0	None
2010-10-03	Isotechnika announces CONFIRM1 clinical trial results at TCT 2010 Symposium	0	None
2010-10-01	Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma	0	None
2010-10-01	LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence	0	None
2010-10-01	AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system	0	None
2010-10-01	Benicar better than Cozaar in reducing blood pressure: Study	0	None
2010-10-01	Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD	0	None
2010-10-01	FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program	0	None
2010-10-01	Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer	0	None
2010-10-01	Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease	0	5
2010-10-01	Achillion initiates ACH-1625 Phase II dosing for HCV infection	0	None
2010-09-30	NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis	0	None
2010-09-30	Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases	0	None
2010-09-30	Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial	0	None
2010-09-30	sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes	0	None
2010-09-30	Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen	0	None
2010-09-30	AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate	0	None
2010-09-30	FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal	0	None
2010-09-30	NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development	0	None
2010-09-30	Circassia announces advancement in T-cell allergy vaccines development	0	None
2010-09-30	ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin	0	None
2010-09-30	Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study	0	None
2010-09-30	Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis	0	None
2010-09-30	ACT updates myoblast program for heart failure treatment	0	5
2010-09-30	Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer	0	None
2010-09-30	Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results	0	None
2010-09-30	Memantine enhances language and communication skills in patients with Alzheimer's disease	0	None
2010-09-29	NEUROKIN accentuates its leadership in the treatment of acute neurological diseases	0	None
2010-09-29	Unique genetic markers point to patient response to SCV-07 treatment	0	None
2010-09-29	Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer	0	5
2010-09-29	Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis	0	None
2010-09-29	Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib	0	None
2010-09-29	Pulmokine receives NIH SBIR grants to develop novel treatments for PAH	0	None
2010-09-29	XOMA completes patient enrollment in XOMA 052 Phase 2a trial	0	None
2010-09-29	NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent	0	None
2010-09-29	ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial	0	None
2010-09-29	Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study	0	None
2010-09-29	Study finds broader statin use as a cost-effective way to prevent heart attack and stroke	0	None
2010-09-29	Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model	0	None
2010-09-29	Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study	0	None
2010-09-29	Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study	0	None
2010-09-29	XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting	0	None
2010-09-29	Further trials needed to determine clinical application of Abatacept in SLE	0	None
2010-09-29	RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV	0	None
2010-09-29	HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug	0	None
2010-09-29	NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate	0	None
2010-09-28	PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections	0	None
2010-09-28	Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients	0	None
2010-09-28	GenMark’s eSensor technology selected for Warfarin clinical study	0	5
2010-09-28	PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity	0	None
2010-09-28	Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting	0	None
2010-09-28	Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC	0	None
2010-09-28	Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity	0	None
2010-09-27	KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT	0	None
2010-09-27	Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients	0	None
2010-09-27	REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference	0	None
2010-09-27	S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer	0	None
2010-09-27	MediciNova receives FDA approval to proceed with initial trial of ibudilast	0	None
2010-09-27	Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients	0	None
2010-09-27	OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer	0	None
2010-09-27	Clinical Data announces Stedivaze agonist data at ASNC2010 meeting	0	None
2010-09-27	Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session	0	None
2010-09-24	Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer	0	None
2010-09-24	Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia	1	None
2010-09-24	Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium	0	None
2010-09-24	Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma	0	4
2010-09-24	Cylene commences CX-4945 Phase I trial in multiple myeloma	0	None
2010-09-24	Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes	0	None
2010-09-24	Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer	0	5
2010-09-23	Tolerx presents otelixizumab preclinical research at 46th EASD	0	None
2010-09-23	FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment	0	None
2010-09-23	Linagliptin clinical trial data shows positive result for type 2 diabetes treatment	0	3
2010-09-23	Athersys presents MultiStem phase I study results at TCT Conference	0	None
2010-09-23	Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria	0	5
2010-09-23	Phase II study: Fostamatinib improves outcomes in RA patients	0	4.3
2010-09-23	Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS	0	5
2010-09-23	DSMB authorizes Oxygen Biotherapeutics' next cohort of Oxycyte emulsion study in severe non-penetrating TBI	0	None
2010-09-23	Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress	0	5
2010-09-23	Weight-based taribavirin reduces anemia, increases sustained virologic response	0	None
2010-09-23	Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes	0	None
2010-09-22	Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD	0	None
2010-09-22	Titan completes enrollment in Probuphine Phase 3 study for opioid addiction	0	None
2010-09-22	Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC	0	5
2010-09-22	Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology	0	None
2010-09-22	Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium	0	None
2010-09-22	Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC	0	None
2010-09-22	FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma	0	None
2010-09-22	Aeras and Crucell commence Phase II study of TB vaccine candidate in infants	0	5
2010-09-22	Novartis' SOM230 reduces cortisol levels in Cushing's disease patients	1	5
2010-09-21	ChemoCentryx presents CCX140 clinical data at EASD	0	None
2010-09-21	NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction	0	None
2010-09-21	VIVUS announces QNEXA study results for obesity treatment	1	None
2010-09-21	Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV	0	None
2010-09-21	ImmunoGen commences clinical testing with SAR566658 anticancer compound	0	None
2010-09-21	Annals of Internal Medicine publishes GRACE study data on HIV therapy	0	None
2010-09-21	ProtAffin presents impressive efficacy data for PA401 in COPD	0	None
2010-09-21	Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study	0	None
2010-09-21	Multinational study demonstrates positive effects of laquinimod in patients with RRMS	0	None
2010-09-21	Lixisenatide experimental diabetes drug shows potential in trial	0	None
2010-09-20	Dengue fever vaccine in the pipeline	0	5
2010-09-20	Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010	0	None
2010-09-20	Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB	0	5
2010-09-20	Micromet initiates MT103 phase 2 trial in adult ALL patients	0	3
2010-09-20	Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients	0	None
2010-09-20	Sanofi-aventis releases Lantus(R) study results for type 2 diabetes	0	None
2010-09-20	Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD	0	None
2010-09-20	Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results	0	None
2010-09-20	Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint	0	None
2010-09-18	ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study	0	None
2010-09-18	Emisphere’s SNAC drug successful in reducing food intake; increasing satiety	0	None
2010-09-18	Minocycline plus N-acetylcysteine may help treat TBI	0	None
2010-09-18	Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer	0	None
2010-09-17	Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress	0	4
2010-09-17	Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes	0	None
2010-09-17	Scott & White Healthcare recruits patients for Phase III lung cancer trial	0	2
2010-09-17	LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine	0	None
2010-09-17	FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency	0	None
2010-09-16	ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease	0	None
2010-09-16	BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout	0	None
2010-09-16	Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment	0	4
2010-09-16	Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC	0	None
2010-09-16	ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010	0	None
2010-09-16	Relypsa announces positive results from Phase 2 clinical trial of RLY5016	0	None
2010-09-16	Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000	0	None
2010-09-15	BioCryst reports results from forodesine studies for CTCL and CLL	0	None
2010-09-15	Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010	0	None
2010-09-15	Phase II clinical trial shows GTx-758 reduces serum free testosterone	0	None
2010-09-15	COTI selected for Canadian life sciences partnering mission	0	None
2010-09-15	ADVENTRX announces Exelbine 12-month stability test results	0	None
2010-09-15	AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website	0	None
2010-09-15	ITS commences treatment in synthetic universal influenza vaccine Phase I trial	0	None
2010-09-15	AMRI selects compound for advanced preclinical testing in treatment of IBS	0	None
2010-09-15	Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer	0	None
2010-09-15	Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference	0	None
2010-09-15	Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder	0	None
2010-09-15	RAB-1 monoclonal antibody study shows positive result for rabies	0	None
2010-09-15	FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy	0	None
2010-09-15	PLX-PAD therapy improves quality of life in CLI patients	0	None
2010-09-15	Wintherix announces WX04554 molecule can cause bone healing	0	None
2010-09-15	Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer	0	5
2010-09-15	Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis	0	None
2010-09-14	Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology	0	None
2010-09-14	Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology	0	None
2010-09-14	Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end	0	None
2010-09-14	VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment	0	None
2010-09-14	TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes	0	None
2010-09-14	Icagen suspends further enrollment in ICA-105665 study	0	None
2010-09-14	AACR, EmergingMed collaborate to connect cancer patients with clinical trials in connection to SU2C broadcast	0	None
2010-09-14	OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia	0	None
2010-09-14	Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation	0	2.5
2010-09-14	Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients	0	5
2010-09-14	Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring	0	None
2010-09-13	High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients	0	None
2010-09-13	Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA	0	None
2010-09-13	Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress	0	None
2010-09-13	North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer	0	None
2010-09-13	Ticagrelor exhibits potential for prevention of heart attacks	0	None
2010-09-13	Synta expands STA-9090 Phase 2 clinical trial in NSCLC	0	None
2010-09-13	Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer	0	5
2010-09-13	Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial	0	None
2010-09-13	Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor	0	None
2010-09-13	ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia	0	None
2010-09-13	XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis	0	None
2010-09-13	Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients	0	None
2010-09-13	Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML	0	None
2010-09-13	Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint	0	None
2010-09-13	Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain	0	None
2010-09-13	Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study	0	None
2010-09-13	Genmab announces Phase II ofatumumab study results in RRMS patients	0	None
2010-09-10	Resverlogix announces key changes to Phase 2 ASSURE trial	0	None
2010-09-10	Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010	0	None
2010-09-10	Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients	0	None
2010-09-10	Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010	0	None
2010-09-10	FerroKin BioSciences initiates international Phase 2 study of FBS0701	0	None
2010-09-10	Allos Therapeutics to present FOLOTYN trial results at ESMO Congress	0	None
2010-09-09	Seaside reports positive data from STX209 Phase 2 study in ASD	2	None
2010-09-09	Acceleron Pharma and Shire announce joint development of ACE-031 for DMD	0	None
2010-09-09	DARA BioSciences presents KRN5500 study results at World Congress on Pain	0	None
2010-09-09	Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion	0	None
2010-09-09	Researchers find minocycline antibiotics effective for fragile X syndrome	0	3
2010-09-09	NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference	0	None
2010-09-09	Insulin may reduce life-threatening bacterial infections in intensive care patients	0	None
2010-09-09	Team of scientists issues HIV vaccine strategy	0	None
2010-09-09	Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010	0	None
2010-09-09	Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop	0	None
2010-09-09	ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM	0	None
2010-09-09	EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients	0	3
2010-09-09	Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children	0	None
2010-09-09	GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL	0	None
2010-09-09	Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference	0	None
2010-09-09	GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'	0	None
2010-09-08	Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation	0	None
2010-09-08	MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial	0	None
2010-09-08	MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE	0	None
2010-09-08	Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors	0	None
2010-09-08	Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic	0	None
2010-09-08	Trius Therapeutics announces presentations from drug development programs at 50th ICAAC	0	None
2010-09-08	PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage	0	None
2010-09-08	N30 Pharmaceuticals commences dosing in N6022 GSNOR trial for asthma, COPD and IBD	0	None
2010-09-08	Phase 3 REALIZE study shows milestone in treatment development for hepatitis C	0	4
2010-09-08	Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer	0	None
2010-09-08	Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy	0	None
2010-09-08	Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program	0	None
2010-09-08	Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment	0	None
2010-09-08	ESPAC-3 trial shows promising results to prevent pancreatic cancer	0	None
2010-09-08	Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome	0	None
2010-09-07	Methylphenidate facilitates recovery from drug addiction	0	None
2010-09-07	Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder	0	None
2010-09-07	CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer	0	None
2010-09-07	Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery	0	None
2010-09-07	Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera	0	None
2010-09-07	TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma	0	None
2010-09-07	Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study	0	None
2010-09-07	Axelar AB publishes first AXL1717 data on phase I/II cancer study	0	None
2010-09-06	Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA	0	None
2010-09-04	AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies	0	None
2010-09-03	Researchers complete INX-189 clinical trials for Hepatitis C virus	0	5
2010-09-03	ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders	0	None
2010-09-03	Data from ESC confirms reduction in adverse events with CYPHER Stent	0	None
2010-09-03	GOG to conduct Phase II trial on primary peritoneal cancer	0	None
2010-09-03	Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection	0	None
2010-09-03	Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology	0	None
2010-09-03	Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer	0	None
2010-09-03	Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan	0	None
2010-09-02	Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress	0	None
2010-09-02	Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20	0	None
2010-09-02	Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections	0	None
2010-09-02	First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer	0	None
2010-09-02	Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints	0	None
2010-09-02	Inhibitex completes INX-189 Phase1a trial for HCV	0	None
2010-09-02	ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint	0	5
2010-09-02	Estradiol prevents vascular permeability following hemorrhagic shock: Study	0	None
2010-09-02	Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer	0	None
2010-09-02	Sangart reports positive MP4OX Phase IIa study data in severely injured trauma patients with hemorrhagic shock	0	None
2010-08-31	Sangart reports positive data from MP4OX Phase IIa study in trauma patients	1	None
2010-08-31	Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study	0	None
2010-08-31	Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin	0	None
2010-08-31	ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients	0	None
2010-08-31	Data monitoring committee recommends early termination following impressive results of AVERROES study	0	None
2010-08-31	Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux	0	None
2010-08-31	Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates	0	2
2010-08-31	Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment	0	None
2010-08-31	Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients	0	None
2010-08-31	Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications	0	None
2010-08-31	J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events	0	None
2010-08-31	Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study	0	None
2010-08-30	Heparin enoxaparin may provide better outcomes than unfractionated heparin	0	None
2010-08-30	Phase 2 INNOVATE PCI trial results for elinogrel presented	0	None
2010-08-30	Smoked cannabis relieves chronic neuropathic pain	1	None
2010-08-30	BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease	0	5
2010-08-30	BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010	0	None
2010-08-30	Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI	0	None
2010-08-30	Selective lowering of heart rate reduces risk of death and hospitalization: Study	0	None
2010-08-30	Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events	0	None
2010-08-30	RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients	0	None
2010-08-30	Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction	0	None
2010-08-30	Boehringer Ingelheim announces sub-analysis result of RE-LY trial	0	None
2010-08-30	ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention	0	None
2010-08-30	Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression	0	None
2010-08-30	TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients	0	None
2010-08-27	Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera	0	None
2010-08-27	Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene	0	None
2010-08-27	FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer	0	5
2010-08-26	Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder	0	None
2010-08-26	Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule	0	None
2010-08-26	NeoPharm second-quarter net loss decreases to $0.8 million	0	None
2010-08-26	Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF	0	None
2010-08-26	FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis	0	None
2010-08-26	Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published	0	None
2010-08-26	Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma	0	None
2010-08-26	FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL	0	None
2010-08-26	Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease	0	None
2010-08-26	Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines	0	None
2010-08-26	Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity	0	None
2010-08-25	CHX reports positive results from final pivotal trial of Prevora antibacterial tooth coating for cavity prevention	0	None
2010-08-25	NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera	0	None
2010-08-25	Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010	0	None
2010-08-25	ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial	0	None
2010-08-25	Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting	0	5
2010-08-25	Eisai's Phase III trial of Perampanel for epilepsy shows positive results	0	None
2010-08-24	First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090	0	None
2010-08-24	FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP	0	None
2010-08-24	Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C	0	None
2010-08-24	USPTO grants Taligen patent for TT30 lead product candidate	0	None
2010-08-24	Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC	0	None
2010-08-24	FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease	0	None
2010-08-23	Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease	0	5
2010-08-23	InSite Vision initiates Phase 1/2 clinical trial of ISV-303	0	None
2010-08-21	Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia	0	3.5
2010-08-21	'Yakult' effective in reducing acute diarrhea in young children: Study	0	None
2010-08-20	Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA	0	None
2010-08-20	Knopp Neurosciences enters $345 million worldwide licensing agreement with Biogen Idec	0	3
2010-08-20	Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment	0	None
2010-08-20	SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program	0	None
2010-08-20	Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug	0	None
2010-08-20	Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer	0	None
2010-08-20	Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa	0	None
2010-08-20	FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD	0	None
2010-08-19	Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study	0	None
2010-08-19	FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer	0	None
2010-08-18	Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS	0	None
2010-08-18	Rush University Medical Center tests new drug therapy for West Nile fever	0	None
2010-08-18	Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease	0	None
2010-08-18	Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate	0	4
2010-08-18	Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002	0	None
2010-08-18	Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols	0	None
2010-08-18	USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody	0	None
2010-08-18	AMT's MAA for LPLD gene therapy product Glybera on schedule	0	None
2010-08-18	Lilly to halt development of potential Alzheimer's disease drug semagacestat	0	None
2010-08-18	Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology	0	None
2010-08-18	BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients	0	None
2010-08-17	Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction	0	None
2010-08-17	Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN	0	None
2010-08-17	Hospitals save $284 million through Premier's Quality Connect quality improvement program	0	None
2010-08-17	Intercell reports significant increase in second quarter revenue	0	None
2010-08-17	Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC	0	5
2010-08-17	Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults	0	None
2010-08-17	Oral contraceptives equally effective for obese women	0	None
2010-08-17	Antidepressant alleviates depression in peri- and postmenopausal women: Study	0	None
2010-08-16	Emisphere second-quarter net loss increases to $13.7 million	0	None
2010-08-16	Liverpool scientists create new drug for malaria	0	4
2010-08-16	Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma	0	None
2010-08-16	Titan Pharmaceuticals second-quarter net loss increases to $1.84 million	0	None
2010-08-16	NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies	0	None
2010-08-16	NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention	0	None
2010-08-16	Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009	0	None
2010-08-16	Belatacept study data to be presented at 23rd International Congress of The Transplantation Society	0	None
2010-08-13	CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial	0	None
2010-08-13	Achillion second-quarter net loss increases to $6.4 million	0	None
2010-08-13	Humanetics Corporation secures license to provide treatment for ionizing radiation exposure	0	None
2010-08-13	Neurologix second-quarter net loss increases to $4.5 million	0	4
2010-08-13	NovaBay second-quarter net loss increases to $1.2 million	0	None
2010-08-13	Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer	0	None
2010-08-13	BioSante second-quarter net loss increases to $10.8 million	0	None
2010-08-13	CPF urges people to consider clinical trials for pulmonary fibrosis	0	None
2010-08-13	Study finds Olaparib can reduce tumor size in ovarian cancer women	0	5
2010-08-13	OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009	0	None
2010-08-13	Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma	0	None
2010-08-13	Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals	0	None
2010-08-13	Arrowhead third-quarter 2010 net loss decreases to $0.4 million	0	None
2010-08-13	Antares Pharma second-quarter total revenue increases 78% to $3.1 million	0	None
2010-08-12	FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients	0	None
2010-08-12	Aeterna Zentaris second-quarter revenues decrease to $5.6 million	0	None
2010-08-12	FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD	0	None
2010-08-12	AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma	0	None
2010-08-12	Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement	0	None
2010-08-12	Early administration of TXA reduces death from bleeding without increase in complications: Study	0	None
2010-08-12	FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine	0	None
2010-08-12	Syndax raises $6 million to support ENCORE 301 study in breast cancer	0	None
2010-08-12	Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer	0	None
2010-08-11	HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies	0	5
2010-08-11	PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints	0	None
2010-08-11	Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch	0	None
2010-08-11	Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes	0	None
2010-08-11	OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients	0	None
2010-08-11	Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma	0	None
2010-08-11	Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache	0	None
2010-08-11	FDA clears Curemark's CM – 4612 IND for Phase III clinical trial in ADHD	0	None
2010-08-11	TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug	0	2
2010-08-11	NIAID launches clinical trials of dengue vaccine	0	None
2010-08-11	Omeros net loss for second-quarter 2010 increases to $7.8 million	0	None
2010-08-10	Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C	0	5
2010-08-10	China Pharma second-quarter revenue increases 22% to $16.6 million	0	None
2010-08-10	Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels	0	None
2010-08-10	Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting	0	None
2010-08-10	Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million	0	None
2010-08-10	Pharmasset third-quarter net loss increases to $16.0 million	0	None
2010-08-10	Synta second-quarter net loss increases to $9.1 million	0	3
2010-08-10	Array BioPharma fiscal 2010 revenue increases to $53.9 million	0	None
2010-08-10	Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease	0	None
2010-08-10	Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011	0	None
2010-08-10	NIH begins human clinical testing for dengue virus vaccine	0	None
2010-08-10	Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial	0	None
2010-08-10	ACADIA second-quarter net loss decreases to $4.3 million	0	None
2010-08-10	Poniard second-quarter net loss decreases to $6.5 million	0	None
2010-08-09	Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer	0	None
2010-08-09	Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year	0	None
2010-08-09	Isis second-quarter pro forma net operating loss increases to $15.5 million	0	None
2010-08-09	Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine	0	5
2010-08-09	Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars	0	None
2010-08-09	Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada	0	4.5
2010-08-09	Clinical Data first-quarter gross revenue increases 52% to $6.2 million	0	None
2010-08-09	Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer	0	None
2010-08-09	GTx second-quarter net loss increases to $12.9 million	0	None
2010-08-09	Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C	0	None
2010-08-07	Ironwood provides investor update for second-quarter 2010	0	None
2010-08-07	EpiCept second-quarter net loss decreases to $4.9 million	0	None
2010-08-07	Ardea Biosciences second-quarter total revenues decline to $3.5 million	0	None
2010-08-07	Orexigen second-quarter net loss decreases to $11.9 million	0	None
2010-08-07	Halozyme second-quarter revenue increases to $3.2 million	0	None
2010-08-07	Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone	0	None
2010-08-07	U.S. Senate passes I-ACT to enable patients with rare disease to participate in clinical trials	0	None
2010-08-07	NeurogesX net loss for second-quarter 2010 increases to $10.2 million	0	None
2010-08-07	Cyclacel second-quarter net loss decreases to $6.5 million	0	None
2010-08-07	Catalyst announces $1.5 million registered direct offering	0	None
2010-08-06	Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials	0	None
2010-08-06	V-101 shows safety profile in treating erythema of rosacea: Clinical study	0	None
2010-08-06	Dyax announces first Phase 3 trial results of KALBITOR for acute HAE	0	None
2010-08-06	Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study	0	None
2010-08-06	TEMPO study recommends early administration of Azilect in PD patients	0	4
2010-08-05	Ligand second-quarter net loss reduces to $0.3 million	0	None
2010-08-05	Biovail second-quarter total revenues increase 23% to $238.8 million	0	None
2010-08-05	Incyte second-quarter total revenues increase to $49.8 million	0	None
2010-08-05	YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis	0	None
2010-08-05	Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million	0	None
2010-08-05	Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer	0	None
2010-08-05	Micromet second-quarter 2010 total revenues increase to $6.5 million	0	None
2010-08-05	Inspire second-quarter total revenue increases 18% to $27.3 million	0	None
2010-08-05	BioCryst second-quarter total revenues increase to $7.6 million	0	None
2010-08-05	CEL-SCI produces and fills first lot of Multikine	0	5
2010-08-05	Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients	0	None
2010-08-05	Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint	1	3
2010-08-05	CTI second-quarter total net operating expenses decrease to $20.0 million	0	None
2010-08-05	ARIAD reports $159.3 million second-quarter net income	0	None
2010-08-05	Genzyme, Isis announce results of two mipomersen phase 3 studies	0	None
2010-08-05	Alnylam second-quarter revenues increase to $26.6 million	0	None
2010-08-05	ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million	0	None
2010-08-05	Anthera second-quarter total operating expenses increase to $7.9 million	0	None
2010-08-05	FDA issues Lux Biosciences Complete Response letter for Luveniq NDA	0	None
2010-08-05	Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation	0	1
2010-08-04	Infinity reports $18.4 million total revenue for second-quarter 2010	0	None
2010-08-04	NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC	0	1
2010-08-04	Contrave added to diet and exercise regimen can induce significant weight loss	0	1
2010-08-04	Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine	0	None
2010-08-04	Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer	0	None
2010-08-04	Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers	0	None
2010-08-04	CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL	0	None
2010-08-04	ZymoGenetics second-quarter net loss declines to $3.8 million	0	None
2010-08-04	Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity	0	None
2010-08-03	Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction	0	None
2010-08-03	Vical second-quarter revenues decrease to $2.1 million	0	None
2010-08-03	First patient treated in Phase Ib expansion study of CUDC-101	0	None
2010-08-03	NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM	0	None
2010-08-03	Researchers call for more public disclosure about clinical drug trials	0	None
2010-08-03	Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma	0	5
2010-08-03	ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC	0	None
2010-08-03	FDA approves N30 Pharma's NDA for N6022 GSNOR	0	None
2010-08-03	Methods to boost neutralizing antibody may prevent HIV-1 transmission	0	None
2010-08-03	Idera announces $15 million registered direct offering	0	None
2010-08-03	Etoricoxib better than opioid drug tramadol for postoperative pain: Study	0	None
2010-08-03	BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria	0	5
2010-08-03	BioMarin reports $0.5 million GAAP net loss for second-quarter 2010	0	None
2010-08-03	BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy	0	None
2010-08-02	Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF	0	5
2010-08-02	Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research	0	None
2010-08-02	Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity	0	None
2010-08-02	HDL does not predict heart attack risk after dramatic statin therapy: Study	0	None
2010-07-30	FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury	0	None
2010-07-30	Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released	0	None
2010-07-30	Anadys Pharmaceuticals reports SVR12 data for ANA598	0	None
2010-07-30	SynCo Bio Partners extends collaboration with Versartis	0	None
2010-07-30	Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study	0	None
2010-07-30	Curaxis completes reverse merger with Auto Search Cars	0	1
2010-07-30	Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus	0	None
2010-07-30	Orexigen's Contrave COR-I trial results published online in journal Lancet	0	None
2010-07-30	Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint	0	5
2010-07-30	ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis	0	None
2010-07-29	Anadys second-quarter net loss decreases to $3.0 million	0	None
2010-07-29	Celgene second-quarter non-GAAP total revenue increases 36% to $850 million	0	None
2010-07-29	AVEO second-quarter total revenues increase to $15.6 million	0	None
2010-07-29	Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment	0	None
2010-07-29	Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials	0	None
2010-07-29	Rotigotine provides clinically relevant improvements in RLS symptoms: Study	0	None
2010-07-29	Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia	0	None
2010-07-29	Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer	0	None
2010-07-29	Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine	0	None
2010-07-29	Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial	0	None
2010-07-29	Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis	0	5
2010-07-29	Etubics enters Phase I trials for next generation vector vaccines	0	None
2010-07-29	CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial	0	None
2010-07-29	Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress	0	None
2010-07-28	Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis	0	5
2010-07-28	Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule	0	None
2010-07-28	Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC	0	None
2010-07-28	Allos reports net loss of $20.0 million for second-quarter 2010	0	None
2010-07-28	Pharmasset announces data from PSI-352938 single ascending dose study	0	None
2010-07-28	BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award	0	None
2010-07-28	Regeneron second-quarter total revenues increase to $115.9 million	0	None
2010-07-28	GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib	0	None
2010-07-28	Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients	0	None
2010-07-28	InterMune second-quarter total revenue decreases to $5.9 million	0	None
2010-07-28	MabCure's MAbs 94% accurate in identifying ovarian cancer	0	None
2010-07-27	Omeros initiates enrollment in OMS302 Phase 2b clinical trial in patients undergoing cataract surgery	0	None
2010-07-27	Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study	0	None
2010-07-27	Study on interactions between new antitubercular drug candidates SQ109 and TMC207	0	None
2010-07-27	Idenix second-quarter total revenues decrease to $1.3 million	0	None
2010-07-26	QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy	0	None
2010-07-26	Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome	0	None
2010-07-26	Can-Fite's CF102 decreases HCV viral load in liver cancer patients	0	5
2010-07-26	Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia	0	None
2010-07-26	AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA	0	None
2010-07-26	Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma	0	None
2010-07-26	Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model	1	5
2010-07-26	ESC concerned over interpretation of JUPITER sub-analysis trial results about HDL cholesterol	0	5
2010-07-26	Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic	0	None
2010-07-26	L2FU reports 100% recovery of recent study's lost clinical trial patients	0	None
2010-07-26	North Shore-LIJ Health System seeks oropharynx patients for phase I clinical trial	0	None
2010-07-26	Experimental treatment for sickle cell disease enters Phase 3 clinical trials	3	2
2010-07-23	First patient enrolled in Phase 3 SyNAPSe study of BHR-100 for TBI	0	4
2010-07-23	Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin	0	None
2010-07-23	Update on Phase III Study of oral calcitonin for treatment of osteoarthritis	0	None
2010-07-23	Novartis, Nordic Bioscience to continue oral calcitonin Phase III study in osteoarthritis patients	0	None
2010-07-23	Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study	0	None
2010-07-23	Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint	0	None
2010-07-23	NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome	0	None
2010-07-23	Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia	0	None
2010-07-23	Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles	0	None
2010-07-22	Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults	0	None
2010-07-22	Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV	0	None
2010-07-22	Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis	0	None
2010-07-22	Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study	0	None
2010-07-22	Repros granted IRB approval to commence low dose Proellex study	0	None
2010-07-22	Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals	0	None
2010-07-22	Fera acquires investigational new drug for treatment of fungal otitis externa	0	None
2010-07-22	Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma	0	4
2010-07-22	Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema	0	4
2010-07-21	AMRI initiates enrollment for Phase I study of ALB-127158 for obesity	0	None
2010-07-21	Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials	0	None
2010-07-21	NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo	0	None
2010-07-21	PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone	0	None
2010-07-21	AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop	0	5
2010-07-21	AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%	1	None
2010-07-21	Major turning point in antiepileptic drug testing, development	0	None
2010-07-20	Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy	0	None
2010-07-20	Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma	0	None
2010-07-20	KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT	0	None
2010-07-20	Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer	0	None
2010-07-20	Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study	0	None
2010-07-20	Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention	0	None
2010-07-20	Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer	0	None
2010-07-20	AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection	0	None
2010-07-20	Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial	0	None
2010-07-20	Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel	0	None
2010-07-20	USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women	0	None
2010-07-20	MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD	0	None
2010-07-20	Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events	0	None
2010-07-20	CytRx updates on progress in clinical development of bafetinib in three oncology indications	0	None
2010-07-20	Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program	0	None
2010-07-20	ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma	0	None
2010-07-20	Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference	0	None
2010-07-20	Benefits of drug L-methionine for neurogenic bladder disorders unclear	0	None
2010-07-19	Amira achieves two clinical development milestones in FLAP program for asthma	0	None
2010-07-19	Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer	0	None
2010-07-19	Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC	0	5
2010-07-19	Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint	0	None
2010-07-19	Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference	0	5
2010-07-19	ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna	0	1
2010-07-19	FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference	0	1
2010-07-17	Pacific Shore releases clinical trial results for Burner Balm lip balm	0	None
2010-07-17	Amgen granted FDA priority review designation for denosumab BLA	0	None
2010-07-16	VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment	0	None
2010-07-16	JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion	0	None
2010-07-16	Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010	0	None
2010-07-15	QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010	0	2
2010-07-15	Positive microplasmin Phase II trial results published in journal Retina	0	None
2010-07-15	Scientists comment on two clinical trials that use Rituximab to treat small-vessel vasculitis	1	None
2010-07-15	PPMD to provide grant to clinical sites participating in Phase 2 study of ACE-031	0	None
2010-07-15	Two patents issued for GlycoMimetics lead drug candidate, related compounds	0	None
2010-07-15	Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction	0	None
2010-07-15	Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma	0	None
2010-07-14	Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial	0	None
2010-07-14	Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis	0	None
2010-07-14	Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects	0	4
2010-07-14	Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults	0	None
2010-07-14	ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML	0	None
2010-07-13	Fredericksburg Oncology invites participants for new metastatic melanoma clinical trial	0	None
2010-07-13	SCENESSE reduces, prevents phototoxic reactions experienced by EPP patients in Phase III trial	0	None
2010-07-13	MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers	0	None
2010-07-13	Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers	0	None
2010-07-13	EntreMed announces publication of preclinical data for ENMD-2076	0	None
2010-07-13	Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women	0	None
2010-07-13	AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke	0	None
2010-07-13	Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate	0	None
2010-07-13	BioSpecifics' partner Auxilium provides update on XIAFLEX	0	None
2010-07-12	Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW	0	None
2010-07-12	Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial	0	None
2010-07-12	Reata funds second pivotal trial of bardoxolone with $78 million equity financing	0	None
2010-07-12	Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1	0	None
2010-07-12	Interim progress from Phase III TeloVac study of GV1001 vaccine announced	0	None
2010-07-12	Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B	0	5
2010-07-12	bitop's Ectoin allergy nasal spray reduces symptoms of acute allergic rhinitis in two-week crossover study	0	None
2010-07-12	Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study	0	None
2010-07-12	Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon	0	None
2010-07-12	Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program	0	None
2010-07-09	Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference	0	None
2010-07-09	Phase II trial results of TB-402 presented at International Congress on Thrombosis	0	None
2010-07-09	Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress	0	None
2010-07-08	Rockwell Medical completes End of Phase II meeting with FDA regarding SFP	0	3
2010-07-08	Advanced Life Sciences announces positive results from preclinical studies of Restanza IV	0	None
2010-07-08	Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR	0	None
2010-07-08	Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program	0	None
2010-07-08	Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH	0	None
2010-07-08	GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches	0	None
2010-07-08	Olaparib shows promising results against inherited forms of breast and ovarian cancer	0	None
2010-07-07	NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36	0	None
2010-07-07	Neoprobe initiates third multi-center Phase 3 clinical study of Lymphoseek	0	None
2010-07-07	Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01	0	None
2010-07-07	Nile completes dosing in CD-NP Phase II study for acute decompensated heart failure	0	None
2010-07-07	Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress	0	None
2010-07-07	Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients	0	None
2010-07-07	Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints	0	None
2010-07-07	Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer	0	None
2010-07-07	Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis	0	None
2010-07-07	Initial Phase II study results of ofatumumab in patients with RRMS announced	0	None
2010-07-07	FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy	0	None
2010-07-07	Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed	0	None
2010-07-07	Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter	0	None
2010-07-07	PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine	0	None
2010-07-07	FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations	0	5
2010-07-06	Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study	0	2
2010-07-06	CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL	0	None
2010-07-06	Nottingham researchers undertake new clinical trial on hearing loss	0	None
2010-07-06	EC approves change in posology of Circadin from 3 weeks to 3 months of treatment	0	None
2010-07-02	Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks	0	None
2010-07-02	Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients	0	None
2010-07-02	Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia	0	1.5
2010-07-02	QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010	0	None
2010-07-02	Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS	0	None
2010-07-02	Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint	0	None
2010-07-01	ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress	0	None
2010-07-01	Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions	0	None
2010-07-01	Oxycyte PFCE decreases mortality after onset of decompression sickness in porcine model study	0	None
2010-07-01	Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010	0	None
2010-07-01	Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study	0	None
2010-07-01	Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis	0	None
2010-07-01	Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression	0	None
2010-07-01	CBio achieves recruitment milestone in XToll clinical trial	0	None
2010-07-01	Biospherics acquires worldwide patent rights to Dtagatose from UKRF	0	None
2010-07-01	XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052	0	None
2010-07-01	Eisai reports preliminary results from Dacogen for Injection Phase III study in AML	0	None
2010-07-01	Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer	0	None
2010-07-01	Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections	0	None
2010-06-30	SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication	0	None
2010-06-30	Calistoga Pharmaceuticals closes $40 million Series C financing	0	None
2010-06-30	Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension	0	None
2010-06-30	BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive	0	None
2010-06-30	Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI	0	None
2010-06-30	Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs	0	None
2010-06-30	European Congress of Nephrology unveils results of various clinical trials	0	3
2010-06-30	Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs	0	None
2010-06-30	Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives	0	None
2010-06-30	Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES	0	None
2010-06-30	Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases	0	None
2010-06-30	Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress	0	None
2010-06-30	Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients	0	None
2010-06-30	FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics	0	None
2010-06-30	Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure	0	None
2010-06-29	Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias	0	None
2010-06-29	Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR	0	None
2010-06-29	Alimera submits Iluvien NDA for DME to FDA	0	None
2010-06-29	Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD	0	None
2010-06-29	Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer	0	None
2010-06-29	Vitae earns $14M milestone payment from Boehringer Ingelheim	0	None
2010-06-29	PROLOR Biotech receives EU GMP certification for hGH-CTP biobetter version of human growth hormone	0	None
2010-06-29	Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis	1	None
2010-06-29	Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics	0	None
2010-06-29	Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication	0	None
2010-06-29	Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer	0	None
2010-06-29	Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients	0	5
2010-06-29	Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA	0	None
2010-06-29	Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma	0	None
2010-06-29	AFREZZA provides long-term glucose control in Type 2 diabetics: Study	0	None
2010-06-29	Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis	0	None
2010-06-29	Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program	0	None
2010-06-29	MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes	0	3
2010-06-29	BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium	0	None
2010-06-29	Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain	0	None
2010-06-29	Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging	0	None
2010-06-28	ITMTX treatment effective in late stages/progressive forms of MS: Study	0	None
2010-06-28	Intarcia presents ITCA 650 Phase 2 study results at 70th ADA	0	None
2010-06-28	Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia	0	3
2010-06-28	Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis	0	None
2010-06-28	MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program	0	None
2010-06-28	Clinical study results show no increased risk of CV events associated with SYMLIN injection	0	None
2010-06-28	Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients	0	None
2010-06-28	First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010	0	None
2010-06-28	Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound	0	5
2010-06-28	Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes	0	None
2010-06-28	RiVax intradermal administration protects from mucosal, systemic ricin intoxication	0	None
2010-06-28	ADVANCE study provides new insights into the management of SHPT in CKD patients	0	None
2010-06-28	Linagliptin mono- and combination therapy improves blood glucose control	0	None
2010-06-28	Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis	0	None
2010-06-28	Final results of VIAject vs. RHI Phase 3 study in type 2 diabetes patients presented at 70th ADA	0	None
2010-06-28	Halozyme presents new data from Ultrafast Insulin development program at 70th ADA	0	None
2010-06-28	Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA	0	None
2010-06-28	Orexigen Therapeutics announces data from CORDiabetes trial for Contrave	0	None
2010-06-28	Arena's lorcaserin reduces body weight across patient subgroups	0	None
2010-06-28	Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer	0	None
2010-06-28	Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010	0	None
2010-06-28	Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study	0	None
2010-06-28	Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar	0	None
2010-06-28	Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010	0	5
2010-06-28	Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE	0	None
2010-06-25	CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial	0	None
2010-06-25	Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen	0	None
2010-06-25	Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated	0	None
2010-06-24	Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin	0	None
2010-06-24	Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease	0	None
2010-06-24	Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies	0	None
2010-06-24	Palatin announces completion of patient dosing, database lock in bremelanotide study for ED	0	None
2010-06-24	AVEO receives EMA orphan medicinal product designation for tivozanib	0	None
2010-06-24	DMARDs should be used early and aggressively at the first sign of RA: Researchers	0	None
2010-06-24	Spherix to explore triglycerides for D-tagatose therapy	0	None
2010-06-24	Pfizer announces suspension of osteoarthritis clinical program for tanezumab	0	1
2010-06-24	Positive results from Phase II PK study for Topical Interferon Alpha-2b announced	0	None
2010-06-24	BioSante closes $15 million registered direct offering	0	None
2010-06-24	Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia	0	None
2010-06-23	Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib	0	None
2010-06-23	SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate	0	None
2010-06-23	AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD	0	None
2010-06-23	Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors	0	None
2010-06-23	MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial	0	None
2010-06-23	New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer	0	None
2010-06-23	Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment	1	4
2010-06-23	Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH	0	None
2010-06-23	MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award	0	None
2010-06-23	Phase I/II clinical trials show crizotinib reduces lung cancer tumors	2	None
2010-06-23	Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology	0	None
2010-06-23	Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients	0	None
2010-06-22	Nuon study confirms potential utility of tranilast as uricosuric agent	0	5
2010-06-22	Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda	0	None
2010-06-22	Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD	0	None
2010-06-22	Biovest targets mantle cell lymphoma as next indication for BiovaxID	0	5
2010-06-22	Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase	0	None
2010-06-22	QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD	0	None
2010-06-22	SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates	0	None
2010-06-22	Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes	1	None
2010-06-22	Oral micronized progesterone effective for women with symptomatic hot flashes	0	None
2010-06-22	Omega-3 effective for treating depression in patients without anxiety disorders	0	None
2010-06-22	FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante	0	None
2010-06-22	Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP	0	None
2010-06-22	Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia	0	None
2010-06-22	Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia	0	None
2010-06-22	Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010	0	None
2010-06-22	Celator announces expansion of research agreement with Cephalon	0	None
2010-06-21	Sinapis initiates dosing in Phase I trial of intravenous infusion of methamphetamine	0	None
2010-06-21	Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study	0	None
2010-06-21	Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications	0	None
2010-06-21	NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection	0	None
2010-06-21	Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010	0	None
2010-06-21	Ostarine increases muscle mass and strength in postmenopausal women: Study	0	4
2010-06-21	Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting	0	None
2010-06-21	ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma	0	None
2010-06-21	Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010	0	None
2010-06-21	OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial	0	None
2010-06-21	Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients	0	None
2010-06-21	Staloral 300 demonstrates efficacy in phase III study for control of asthma in China	0	5
2010-06-21	Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1	0	4
2010-06-19	New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James	0	5
2010-06-19	Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010	0	None
2010-06-18	Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome	0	None
2010-06-18	Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR	0	None
2010-06-18	Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS	0	None
2010-06-18	InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting	0	None
2010-06-18	BioSante announces presentation of LibiGel safety update at ENDO 2010	0	None
2010-06-18	Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010	0	None
2010-06-18	Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010	0	None
2010-06-18	DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications	0	None
2010-06-18	Roche implements risk mitigation plan in taspoglutide Phase III programme	0	None
2010-06-18	First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer	0	None
2010-06-18	EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment	0	None
2010-06-17	First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010	0	None
2010-06-17	Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders	0	None
2010-06-17	Teva exercises option to invest additional $11.9M in Andromeda Biotech	0	None
2010-06-17	Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting	0	None
2010-06-17	Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes	0	None
2010-06-17	VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR	0	None
2010-06-17	Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR	0	None
2010-06-17	HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010	0	None
2010-06-17	Stimuvax clinical program resumed in patients with NSCLC	0	None
2010-06-17	Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC	0	None
2010-06-17	Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer	0	4
2010-06-17	DURECT reports European POSIDUR Phase IIb hysterectomy clinical trial results	0	None
2010-06-16	The utility of observational studies in clinical decision making: Lessons learned from statin trials	0	None
2010-06-16	Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI	0	None
2010-06-16	Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease	0	None
2010-06-16	OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC	0	None
2010-06-16	Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA	0	5
2010-06-16	RG7204 holds promise for metastatic melanoma with V600E BRAF mutation	0	None
2010-06-16	Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE	0	5
2010-06-16	Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint	0	None
2010-06-16	AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib	0	None
2010-06-16	Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain	0	None
2010-06-16	Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma	0	None
2010-06-16	Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist	0	None
2010-06-16	NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex	0	5
2010-06-16	Nymox near completion of new NX-1207 follow-up study for BPH	0	None
2010-06-16	New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA	0	None
2010-06-16	Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress	0	None
2010-06-16	Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress	0	None
2010-06-16	Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma	0	None
2010-06-15	Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis	0	None
2010-06-15	Anacor's AN3365 novel systemic antibiotic achieves proof of concept	0	None
2010-06-15	Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced	0	None
2010-06-15	Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation	1	None
2010-06-15	Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine	0	None
2010-06-15	Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer	0	None
2010-06-15	First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma	0	None
2010-06-15	Early administration of tranexamic acid to patients with severe bleeding injuries saves lives	0	None
2010-06-15	Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO	0	None
2010-06-15	Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL	0	None
2010-06-15	Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA	0	None
2010-06-15	Celator presents new data on CPX-351 liposome injection at European Hematology Association congress	0	None
2010-06-15	FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS	0	None
2010-06-14	MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK	0	None
2010-06-14	Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy	0	None
2010-06-14	Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress	0	5
2010-06-14	Lantheus Medical Imaging reports new Phase 4 data from DEFINITY study	0	None
2010-06-14	Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010	0	4
2010-06-14	Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC	0	None
2010-06-14	Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010	0	None
2010-06-14	ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate	0	None
2010-06-14	Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC	0	None
2010-06-14	Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS	0	None
2010-06-14	Chiasma successfully completes Phase I clinical study of Octreolin	0	None
2010-06-11	Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010	0	None
2010-06-11	Phase II study results of riociguat for CTEPH and PAH published online	0	None
2010-06-11	Trevena's scientists present research data on GPCR biased ligands at two scientific conferences	0	None
2010-06-11	Otonomy completes $10 million Series A financing with Avalon Ventures	0	None
2010-06-11	AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting	0	None
2010-06-11	Clinical data from investigational study of patients with multiple myeloma presented at ASCO	0	2
2010-06-11	Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma	0	None
2010-06-11	Repros receives FDA confirmation on lifting of full clinical hold on Proellex	0	None
2010-06-11	Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL	0	None
2010-06-11	Helix BioPharma third-quarter revenues increase 20.6%	0	None
2010-06-11	Bevacizumab effective for treatment of wet AMD: Study	0	None
2010-06-11	AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics	0	None
2010-06-11	Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy	0	5
2010-06-11	FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS	0	4
2010-06-10	Idenix initiates IDX320 proof-of-concept study for HCV infection	0	None
2010-06-10	FDA grants Collegium Fast Track designation for COL-172 opioid formulation	0	None
2010-06-10	MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS	0	None
2010-06-10	Allopurinol exhibits potential benefits for CKD patients	0	5
2010-06-10	Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin	0	5
2010-06-10	Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology	0	None
2010-06-10	Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients	0	None
2010-06-10	Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer	0	None
2010-06-10	Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM	0	5
2010-06-10	Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer	0	None
2010-06-10	TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer	0	None
2010-06-10	CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks	0	None
2010-06-10	Combination therapy appears to improve outcome of women with late-stage ovarian cancer	0	None
2010-06-10	Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer	0	None
2010-06-09	NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain	0	None
2010-06-09	Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy	0	5
2010-06-09	Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting	0	None
2010-06-09	S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis	0	None
2010-06-09	First clinical trial among African women to test vaginal ring that prevents HIV transmission	0	None
2010-06-09	Repligen's fiscal 2010 total revenue decreases to $20,971,000	0	None
2010-06-09	Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure	0	None
2010-06-09	Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol	0	None
2010-06-09	Update on Phase II clinical study of CH-4051 in rheumatoid arthritis	0	None
2010-06-09	Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma	0	None
2010-06-09	Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO	0	4
2010-06-09	Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure	0	None
2010-06-09	Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors	0	5
2010-06-09	Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting	0	None
2010-06-09	Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent	0	None
2010-06-09	Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010	0	None
2010-06-09	GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting	0	3.5
2010-06-09	Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients	0	5
2010-06-09	Pharnext closes €4.8-million Series A funding round	0	None
2010-06-09	Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study	0	2
2010-06-09	Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts	0	None
2010-06-09	PharmaMar commences Aplidin Phase III registration trial for multiple myeloma	0	None
2010-06-09	Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint	0	None
2010-06-08	Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO	0	None
2010-06-08	NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates	0	None
2010-06-08	Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer	0	None
2010-06-08	Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma	0	None
2010-06-08	GTx reports positive results from toremifene Phase III clinical trial	0	None
2010-06-08	Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases	0	None
2010-06-08	Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial	0	None
2010-06-08	Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010	0	None
2010-06-08	TG-MV-006 study: Microplasmin shows promise for treatment of VMA, MH	0	None
2010-06-08	Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas	0	None
2010-06-08	Scientists combine two agents to treat patients with multiple myeloma	0	None
2010-06-08	Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer	0	None
2010-06-08	Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO	0	None
2010-06-08	Chemotherapy drug sunitinib promising for HIV-positive cancer patients	0	None
2010-06-08	Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL	0	None
2010-06-08	Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO	0	None
2010-06-08	Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study	0	None
2010-06-08	Genta presents tesetaxel dose-ranging trial results at ASCO 2010	0	None
2010-06-08	Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010	0	None
2010-06-08	Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010	0	None
2010-06-08	GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010	0	None
2010-06-08	Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO	0	None
2010-06-08	Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010	0	None
2010-06-08	Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO	0	5
2010-06-08	ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO	0	None
2010-06-08	Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer	0	None
2010-06-08	Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010	0	None
2010-06-08	ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO	0	None
2010-06-08	Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010	0	None
2010-06-08	First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting	0	None
2010-06-08	Erlotinib can reduce lung cancer death by 26% : Study	0	None
2010-06-08	Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO	0	None
2010-06-08	Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes	0	None
2010-06-07	Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer	0	None
2010-06-07	XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury	0	None
2010-06-07	Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported	0	None
2010-06-07	Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting	0	None
2010-06-07	Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010	0	None
2010-06-07	Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010	0	None
2010-06-07	Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting	0	None
2010-06-07	Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO	0	None
2010-06-07	Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer	0	None
2010-06-07	OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors	0	None
2010-06-07	Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx	0	None
2010-06-07	EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published	0	None
2010-06-07	Oncolytics reports updated results from U.K. Phase I/II combination REOLYSIN trial at ASCO 2010	0	None
2010-06-07	Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010	0	None
2010-06-07	Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes	0	5
2010-06-07	Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting	0	None
2010-06-07	Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer	0	None
2010-06-07	Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis	0	5
2010-06-07	Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma	0	None
2010-06-07	Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease	0	None
2010-06-07	Cytheris completes €12 million Series D financing	0	None
2010-06-07	Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations	0	None
2010-06-07	Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis	0	None
2010-06-07	AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer	0	None
2010-06-07	Genta reports combined data from Genasense Phase 3 trials for advanced melanoma	0	None
2010-06-07	Bevacizumab extends progression-free survival in women with advanced ovarian cancer	0	None
2010-06-07	Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL	0	None
2010-06-07	The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug	0	None
2010-06-07	Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients	0	None
2010-06-07	Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR	0	None
2010-06-07	Ipilimumab extends survival of metastatic melanoma patients: Study	0	None
2010-06-07	Updated phase II study results of OPAXIO in patients with advanced esophageal cancer	0	None
2010-06-07	Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO	0	None
2010-06-07	MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy	0	None
2010-06-07	Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs	0	None
2010-06-07	Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer	0	None
2010-06-07	Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma	0	None
2010-06-07	Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma	0	None
2010-06-07	Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer	0	None
2010-06-07	Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma	0	None
2010-06-07	Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010	0	None
2010-06-07	Poniard reports positive data from Phase 3 SPEAR trial of picoplatin for SCLC	0	None
2010-06-07	Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study	0	None
2010-06-07	OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO	0	None
2010-06-07	Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO	0	None
2010-06-07	Microplasmin exhibits potential to cure 50% of patients with macular hole	0	None
2010-06-07	Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer	0	None
2010-06-07	Phase II study results of pomalidomide, dexamethasone for multiple myeloma presented at ASCO	0	None
2010-06-07	Selenium not beneficial in reducing risk of lung cancer development	0	None
2010-06-07	AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment	0	None
2010-06-07	Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO	0	None
2010-06-07	ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO	0	None
2010-06-07	ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint	0	None
2010-06-07	Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer	0	None
2010-06-07	Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC	0	None
2010-06-07	Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010	0	None
2010-06-07	ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010	0	None
2010-06-05	Positive results from new analyses of denosumab Phase 3 trials	0	None
2010-06-05	Celgene reports initial data from investigator-initiated study of REVLIMID	0	None
2010-06-05	Millennium announces data on VELCADE in treatment of patients with amyloidosis	0	None
2010-06-05	Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody	0	None
2010-06-05	Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO	0	None
2010-06-05	Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC	0	None
2010-06-05	Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer	0	None
2010-06-05	Green tea component reduces leukemia cells in patients with CLL	0	4
2010-06-05	Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma	0	None
2010-06-05	Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010	0	None
2010-06-05	RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa	0	3.3
2010-06-04	Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO	0	None
2010-06-04	Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC	0	None
2010-06-04	Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND	0	None
2010-06-04	Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy	0	None
2010-06-04	Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010	0	None
2010-06-04	Study of methylphenidate for cancer-related fatigue benefits patients with stage III/IV disease	0	None
2010-06-04	Oxycyte perfluorocarbon emulsion demonstrates marked neuroprotective effect in rat model of spinal cord injury	0	None
2010-06-04	Ongoing clinical development program for NX-1207 for treatment of BPH highlighted	0	None
2010-06-04	Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO	0	None
2010-06-04	R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa	0	None
2010-06-04	Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress	0	None
2010-06-04	PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids	0	None
2010-06-04	Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome	0	None
2010-06-03	Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix	0	1
2010-06-03	Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon	0	None
2010-06-03	Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint	0	None
2010-06-03	NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed	0	None
2010-06-02	Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO	0	None
2010-06-02	Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH	0	None
2010-06-02	ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study	0	None
2010-06-02	ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C	1	None
2010-06-02	Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010	0	None
2010-06-02	Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer	0	None
2010-06-02	Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea	0	None
2010-06-02	Curemark commences clinical trial enrollment for CM-AT autism treatment at two more sites	0	None
2010-06-02	Azithromycin as effective as penicillin for early-stage syphilis: Study	0	3
2010-06-02	Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA	0	None
2010-06-02	Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress	0	None
2010-06-02	Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer	0	None
2010-06-02	HTDS commences clinical trials for MEVAC-A vaccine in Vietnam	0	None
2010-06-02	Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online	0	None
2010-06-01	Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting	0	None
2010-06-01	Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers	0	None
2010-06-01	Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed	0	None
2010-06-01	BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients	0	None
2010-06-01	Centocor Ortho Biotech acquires RespiVert	0	None
2010-06-01	Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA	0	None
2010-06-01	Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting	0	None
2010-05-31	FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency	0	None
2010-05-31	Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine	0	None
2010-05-31	Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients	0	None
2010-05-31	Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010	0	None
2010-05-29	Sunitinib not effective in patients with papillary RCC: Researchers	0	None
2010-05-29	CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia	0	None
2010-05-28	Advaxis doses first patient in FDA-approved phase II CIN trial	0	None
2010-05-28	Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress	0	None
2010-05-28	VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010	0	None
2010-05-28	Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's	0	None
2010-05-28	Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH	0	None
2010-05-28	CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial	0	None
2010-05-28	ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine	0	None
2010-05-27	NOXXON Pharma closes €33 million Series D round of financing	0	None
2010-05-27	Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy	0	None
2010-05-27	YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC	0	None
2010-05-27	Pfizer plans recruitment halt to EMPHASIS-HF trial	0	None
2010-05-27	FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging	0	None
2010-05-27	Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer	0	None
2010-05-27	Patients with transformed lymphoma show positive response to lenalidomide: Research	0	None
2010-05-27	New study holds promise for patients with LCA	0	None
2010-05-27	Logical Therapeutics closes $16.9 million Series C equity financing round	0	None
2010-05-26	CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer	0	None
2010-05-26	Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development	0	None
2010-05-26	Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability	0	5
2010-05-26	Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016	0	None
2010-05-26	Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH	0	None
2010-05-26	Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept	0	None
2010-05-26	Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen	0	5
2010-05-26	GTx reports top line results from toremifene Phase III clinical trial for prostate cancer	0	None
2010-05-25	Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress	0	None
2010-05-25	CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers	0	5
2010-05-25	Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients	0	None
2010-05-25	Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010	0	None
2010-05-25	REDUCE trial data published in the online version of European Urology	0	4
2010-05-25	DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis	0	None
2010-05-25	ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO	0	None
2010-05-25	NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo	0	None
2010-05-25	Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS	0	None
2010-05-25	Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting	0	None
2010-05-25	Neuralstem updates progress of ongoing Phase I human clinical trial for ALS	0	5
2010-05-25	Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC	0	None
2010-05-24	Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA	0	None
2010-05-24	Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed	0	None
2010-05-24	Phase 1 clinical trial of OXY111A initiated	0	None
2010-05-24	Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA	0	None
2010-05-24	Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol	0	None
2010-05-21	Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC	0	None
2010-05-21	New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010	0	None
2010-05-21	ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO	0	None
2010-05-21	Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010	0	None
2010-05-21	Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program	0	None
2010-05-21	ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO	0	None
2010-05-21	Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO	0	None
2010-05-21	PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting	0	None
2010-05-21	Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN	0	None
2010-05-21	Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010	0	None
2010-05-21	New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting	0	None
2010-05-21	Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome	0	4.5
2010-05-21	Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO	0	None
2010-05-21	Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO	0	None
2010-05-21	ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting	0	None
2010-05-21	Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting	0	None
2010-05-21	Phase III PRIMA study data of Rituxan to be featured at 46th ASCO	0	None
2010-05-21	Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation	0	None
2010-05-21	Genentech to present new data for targeted cancer medicines at 46th ASCO	0	None
2010-05-21	Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO	0	None
2010-05-21	Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010	0	None
2010-05-21	Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO	0	None
2010-05-21	ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting	0	None
2010-05-21	Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients	0	None
2010-05-21	Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010	0	None
2010-05-21	Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010	0	None
2010-05-21	Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO	0	None
2010-05-21	Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer	0	None
2010-05-20	Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma	0	None
2010-05-20	Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial	0	None
2010-05-20	Update on Phase I clinical trials of Oncopore for treatment of cancer	0	None
2010-05-20	Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever	0	None
2010-05-20	Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies	0	None
2010-05-19	Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD	0	None
2010-05-19	Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010	0	None
2010-05-19	Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients	0	None
2010-05-19	Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS	0	None
2010-05-19	Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen	0	None
2010-05-19	Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials	0	None
2010-05-19	Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin	2	2
2010-05-19	Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product	0	None
2010-05-19	New multi-center follow-up study of NX-1207 for treatment of BPH to be completed	0	None
2010-05-19	Generex Biotechnology's Phase I study data of AE37 for prostate cancer published	0	None
2010-05-19	Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA	0	None
2010-05-19	Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder	0	4
2010-05-19	Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting	0	None
2010-05-19	Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer	0	None
2010-05-18	Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting	0	None
2010-05-18	Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial	0	None
2010-05-18	KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection	0	None
2010-05-18	Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine	0	None
2010-05-18	Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes	0	None
2010-05-18	Phase II ALSTAR trial: Talampanel is safe for ALS patients	0	5
2010-05-18	UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems	0	5
2010-05-18	FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis	0	4.2
2010-05-17	BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron	0	None
2010-05-17	Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting	0	None
2010-05-17	FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF	0	None
2010-05-17	Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR	0	None
2010-05-17	Hemispherx Biopharma to conduct study of Ampligen antiviral in China	0	None
2010-05-17	ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial	0	None
2010-05-17	Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review	0	None
2010-05-17	Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer	0	None
2010-05-17	Tranzyme Pharma to present data on prokinetic agent TZP-101 in GI recovery at ASCRS 2010	0	None
2010-05-17	Polypill to be tested in new heart disease trial	1	None
2010-05-17	Roche to commence clinical study of TB-403 in patients with colorectal and ovarian cancer	0	None
2010-05-17	Treatment with MP-376 reduces P. aeruginosa in CF patients: Research	0	None
2010-05-15	Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections	0	5
2010-05-15	Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection	0	None
2010-05-14	Data from RGN-259 study published in Archives of Ophthalmology	0	None
2010-05-14	Phase 2a study results of Aerosurf for prevention of RDS in premature infants published	0	None
2010-05-14	Inhibitex reports net loss of $4.8M for first-quarter 2010	0	None
2010-05-14	International study to test effectiveness of celecoxib in preventing growth of precancerous polyps	0	None
2010-05-14	DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary liver cancer	0	None
2010-05-14	Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting	0	None
2010-05-14	Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010	0	None
2010-05-14	Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010	0	None
2010-05-14	RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug	0	None
2010-05-14	Derma Sciences first-quarter net sales up 23% to $12,844,382	0	None
2010-05-14	Chimerix commences first-in-human study of CMX157 for HIV	0	None
2010-05-13	Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED	0	None
2010-05-13	ARYx Therapeutics decreases first-quarter net loss to $6.4 million	0	None
2010-05-13	Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia	1	5
2010-05-13	Genta first-quarter net loss increases to $166.6 million	0	None
2010-05-13	Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010	0	None
2010-05-13	Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087	0	None
2010-05-13	Amarin reports cash balance of $44 million for first-quarter 2010	0	None
2010-05-13	Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates	0	None
2010-05-13	CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer	0	None
2010-05-13	Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule	0	None
2010-05-12	Avexa halts HIV drug trials	0	None
2010-05-12	GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010	0	None
2010-05-12	NovaBay first-quarter net loss increases to $1.6 million	0	None
2010-05-12	Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010	0	None
2010-05-12	Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials	0	None
2010-05-12	FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer	0	None
2010-05-12	Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD	0	None
2010-05-12	Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients	0	None
2010-05-12	Evotec first-quarter operating loss decreases 93% to € 1.5 m	0	None
2010-05-12	COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate	0	None
2010-05-12	NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents	0	None
2010-05-12	Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs	0	None
2010-05-12	Oncos Therapeutics completes € 4 million investment from HealthCap	0	4
2010-05-12	Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients	0	None
2010-05-12	Gilead Sciences board authorizes $5 billion common stock repurchase program	0	None
2010-05-12	ChronTech Pharma receives six months' extension to buy back in ChronSeal ownership	0	None
2010-05-12	Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services	0	None
2010-05-12	Update on Nymox Pharmaceutical's Phase 3 program for NX-1207	0	None
2010-05-12	Tianyin third-quarter revenue up 60%	0	None
2010-05-12	Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease	0	None
2010-05-12	Exelixis first-quarter revenues increase to $42.2 million	0	None
2010-05-12	Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients	0	None
2010-05-12	Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported	0	None
2010-05-11	Pro-Pharmaceuticals completes $6 million private placement with 10X Fund	0	None
2010-05-11	EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer	0	None
2010-05-11	China Pharma first-quarter revenue up 16% to $15.1 million	0	None
2010-05-11	DUSA Pharmaceuticals first-quarter total product revenues up 22%	0	None
2010-05-11	MediciNova announces $15 million senior secured term loan with Oxford Finance	0	None
2010-05-11	Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens	0	None
2010-05-11	Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference	0	None
2010-05-11	Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010	0	None
2010-05-11	Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million	0	None
2010-05-11	CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate	0	None
2010-05-10	Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn	0	None
2010-05-10	Enzon reports income from continuing operations of $20.8M for first-quarter 2010	0	None
2010-05-10	QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain	0	None
2010-05-10	Harbor BioSciences reports encouraging results from Triolex Phase IIa trials	0	None
2010-05-10	Immunomedics third-quarter revenues increase to $10.7 million	0	None
2010-05-10	European patent strengthens Soligenix' topically active steroid intellectual property portfolio	0	None
2010-05-10	Achillion reports lower net loss of $5.6M for first-quarter 2010	0	None
2010-05-10	MicroStockProfit.com features investment report on ARIAD Pharmaceuticals	0	None
2010-05-10	Lexicon Pharmaceuticals first-quarter revenues down 61%	0	5
2010-05-10	Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei	0	None
2010-05-07	Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting	0	5
2010-05-07	Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010	0	None
2010-05-07	Osiris Therapeutics reports net income of $2.4M for first-quarter 2010	0	None
2010-05-07	Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure	0	None
2010-05-07	Halozyme Therapeutics first-quarter net loss decreases to $11.8 million	0	None
2010-05-07	MicroStockProfit.com releases NexMed investment report	0	None
2010-05-07	Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010	0	None
2010-05-07	Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting	0	None
2010-05-07	Genzyme to initiate $2 billion stock buyback	0	None
2010-05-07	Nabi Biopharmaceuticals reports first-quarter net income of $5.5 million from continuing operations	0	None
2010-05-07	Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule	0	None
2010-05-06	Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex	0	None
2010-05-06	Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients	0	None
2010-05-06	PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis	0	5
2010-05-06	Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million	0	None
2010-05-06	Vical reports net loss of $8.5 million for first-quarter 2010	0	None
2010-05-06	Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin	0	None
2010-05-06	Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease	0	None
2010-05-06	CU-Boulder develops inhalable vaccine for measles prevention	0	None
2010-05-06	Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010	0	None
2010-05-06	ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE	0	None
2010-05-06	Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010	0	None
2010-05-06	Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010	0	None
2010-05-06	Positive results from Phase IIa clinical study of LIPO-102	0	None
2010-05-06	Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416	0	None
2010-05-06	Update on CEL-SCI's Phase III clinical trial of Multikine	0	None
2010-05-06	Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX	0	None
2010-05-05	Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients	0	None
2010-05-05	Rockwell Medical first-quarter sales up 17.1%	0	None
2010-05-05	Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma	0	None
2010-05-05	Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin	0	None
2010-05-05	AMRI first-quarter total revenue down 9% to $49.3 million	0	None
2010-05-05	Cadence Pharmaceuticals resubmits OFIRMEV NDA	0	None
2010-05-05	Merck acquires development, commercialization rights of ridaforolimus	0	None
2010-05-05	ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor	0	None
2010-05-05	Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine	0	None
2010-05-05	Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis	0	None
2010-05-05	UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine	0	None
2010-05-05	Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study	0	None
2010-05-05	StemCells first-quarter total revenue up 307%	0	None
2010-05-05	Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010	0	None
2010-05-05	ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial	0	None
2010-05-05	Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies	0	None
2010-05-05	S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors	0	None
2010-05-05	Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010	0	None
2010-05-05	Additional pivotal Phase 3 trial data for MoxDuo IR released	0	None
2010-05-05	Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH	0	None
2010-05-05	Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010	0	5
2010-05-05	BELLUS Health to discontinue NC-503 diabetes development program	0	None
2010-05-04	MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010	0	None
2010-05-04	Celldex reports net loss of $6.6 million for first-quarter 2010	0	None
2010-05-04	Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010	0	None
2010-05-04	Celsion reports $4.6 million net loss from operations for first-quarter 2010	0	None
2010-05-04	Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI	0	None
2010-05-04	Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com	0	None
2010-05-04	MicroStockProfit.com releases investment report on Vical	0	None
2010-05-04	Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS	0	None
2010-05-04	ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine	0	None
2010-05-04	Hologic commences enrollment in European trial of Gestiva for prevention of recurrent preterm birth	0	None
2010-05-04	Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010	0	None
2010-05-04	Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010	0	None
2010-05-04	Researchers present positive results of Phase II clinical trial of eliglustat tartrate	0	None
2010-05-04	Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010	0	None
2010-05-03	NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12	0	None
2010-05-03	NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis	0	None
2010-05-03	Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells	0	None
2010-05-03	Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting	0	None
2010-05-03	Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease	0	None
2010-05-03	ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM	0	5
2010-05-03	Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor	0	None
2010-05-03	BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development	0	None
2010-05-03	Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010	0	None
2010-05-03	AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010	0	None
2010-05-03	Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery	0	None
2010-05-03	Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments	0	None
2010-05-03	TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH	0	None
2010-05-03	SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit	0	None
2010-05-03	Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH	0	None
2010-05-03	Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study	0	3
2010-05-03	Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure	0	None
2010-05-03	Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials	0	None
2010-05-03	Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference	0	None
2010-05-03	FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer	0	None
2010-04-30	GeNOsys sponsors Phase I safety trial in collaboration with Nitric Solutions	0	None
2010-04-30	Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound	0	None
2010-04-30	Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis	0	None
2010-04-30	Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder	0	None
2010-04-30	Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex	0	None
2010-04-30	Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults	0	None
2010-04-30	TenX Biopharma signs Clinical Trial Agreement with NCI	0	None
2010-04-30	Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials	0	None
2010-04-30	EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout	0	None
2010-04-30	Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan	0	None
2010-04-30	Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC	0	None
2010-04-29	Celgene's first-quarter non-GAAP total revenue up 31% to $789 million	0	None
2010-04-29	Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma	0	None
2010-04-29	Human Genome Sciences reports net loss of $47.9M for first-quarter 2010	0	None
2010-04-29	AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010	0	None
2010-04-29	Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment	0	None
2010-04-29	Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI	0	None
2010-04-29	Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting	0	None
2010-04-29	CINJ trial targets new combination therapy for advanced solid tumors	0	None
2010-04-29	Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010	0	None
2010-04-29	Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics	0	None
2010-04-29	Geron reports net loss of $16.6M for first-quarter 2010	0	None
2010-04-29	Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis	0	5
2010-04-29	Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients	0	None
2010-04-29	Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint	0	None
2010-04-29	Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease	0	None
2010-04-29	Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated	0	None
2010-04-28	Positive results from interim analysis of ongoing Phase 2a study of BCX4208	0	None
2010-04-28	Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch	0	None
2010-04-28	BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine	0	None
2010-04-28	Seattle Genetics reports revenues of $46.5M for first-quarter 2010	0	None
2010-04-28	Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010	0	None
2010-04-28	Update on ICA-105665 clinical development plans for treatment of epilepsy and pain	0	None
2010-04-28	ChronSeal multi-center study in Sweden and Norway finalized	0	None
2010-04-28	DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients	0	None
2010-04-28	NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer	0	None
2010-04-28	Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010	0	None
2010-04-28	Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets	0	None
2010-04-28	Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress	0	None
2010-04-27	Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor	0	None
2010-04-27	Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS	0	None
2010-04-27	Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI	0	None
2010-04-27	ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE	0	None
2010-04-27	Prime-boost malaria vaccine regimen provides sterile protection: Vical	0	5
2010-04-27	UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV	0	None
2010-04-27	LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand	0	None
2010-04-27	Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme	0	None
2010-04-27	Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting	0	None
2010-04-27	Phase 2b clinical study initiated to evaluate GI safety of LT-NS001	0	None
2010-04-27	FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco	0	None
2010-04-26	OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva	0	None
2010-04-26	First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD	0	None
2010-04-26	Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer	0	None
2010-04-26	Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting	0	None
2010-04-24	Recent business progress at Penwest Pharmaceuticals	0	None
2010-04-24	Study finds AFREZZA comparable to standard of care insulin therapy	0	None
2010-04-24	Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study	0	None
2010-04-24	Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program	0	None
2010-04-24	AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing	0	None
2010-04-23	Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas	0	None
2010-04-23	Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010	0	1
2010-04-23	Affymax institutes quiet period in connection with Hematide Phase 3 result analysis	0	None
2010-04-23	Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor	0	None
2010-04-23	Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress	0	None
2010-04-23	Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research	0	None
2010-04-23	Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting	0	5
2010-04-23	Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation	0	None
2010-04-23	Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC	0	None
2010-04-23	Aragon Pharmaceuticals raises $22M through Series B financing	0	None
2010-04-22	Karo Bio reports net loss of MSEK 40.5 for January–March 2010	0	None
2010-04-22	Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated	0	None
2010-04-22	Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress	0	None
2010-04-22	Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth	0	None
2010-04-22	Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium	2	None
2010-04-22	Positive results from preclinical EP-302 program presented at AACR 2010	0	None
2010-04-22	AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR	0	None
2010-04-22	PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting	1	None
2010-04-22	ImmunoCellular Therapeutics, UPENN sign research agreement	0	None
2010-04-22	Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting	0	None
2010-04-22	Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR	0	None
2010-04-22	NO-naproxen blocks molecular changes leading to colorectal cancer development	0	None
2010-04-22	Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients	0	None
2010-04-22	Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer	0	None
2010-04-22	Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases	0	None
2010-04-21	Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs	0	None
2010-04-21	HemaQuest Pharmaceuticals closes $12M Series B financing	0	None
2010-04-21	Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing	0	None
2010-04-21	Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously	0	None
2010-04-21	Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010	0	None
2010-04-21	Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010	0	None
2010-04-21	Initial results of gallium-containing compound to treat serious infection presented at AACR 2010	0	5
2010-04-21	ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting	0	None
2010-04-21	Preclinical data in neuroblastoma for perifosine to be presented at AACR 2010 Meeting	0	None
2010-04-21	Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies	0	None
2010-04-21	Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand	0	None
2010-04-21	Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval	0	None
2010-04-21	Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress	0	None
2010-04-21	IMPACT trial shows improvement in OS for metastatic CRPC	0	None
2010-04-21	Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells	0	None
2010-04-21	Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS	0	None
2010-04-20	Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus	0	None
2010-04-20	NeoPharm commences enrollment in Phase II clinical trial of LE-DT for pancreatic cancer	0	None
2010-04-20	Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients	0	None
2010-04-20	Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010	0	None
2010-04-20	Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting	0	None
2010-04-20	Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis	0	None
2010-04-20	NanoBio to develop intranasal vaccine for HBV	0	None
2010-04-20	Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy	0	None
2010-04-20	XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels	0	None
2010-04-20	Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR	0	None
2010-04-20	On-going phase II trial of octagam in AD to be discussed at ICAD 2010	0	None
2010-04-20	Statin use may increase risk of developing benign colorectal tumors: APC trial	0	None
2010-04-20	ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint	0	None
2010-04-20	Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy	0	None
2010-04-20	Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies	0	None
2010-04-20	Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C	0	None
2010-04-19	Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer	0	None
2010-04-19	Raloxifene, tamoxifen remain effective options in prevention of breast cancer, finds 19,490-patient study	0	None
2010-04-19	Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010	0	None
2010-04-19	Jennerex presents positive interim data from Phase 2 clinical trial of JX-594 for HCC at 45th EASL	0	None
2010-04-19	Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals	0	None
2010-04-19	Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood	0	None
2010-04-19	Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010	0	None
2010-04-19	Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC	0	4
2010-04-19	Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus	0	None
2010-04-19	Stallergenes' US phase III clinical trial of Oralair achieves primary endpoint	0	5
2010-04-19	Amgen announces results from pivotal Phase 3 "408" trial of Vectibix	0	None
2010-04-19	Results of BATTLE Trial presented at AACR 2010	0	None
2010-04-19	Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress	0	None
2010-04-17	G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks	0	None
2010-04-17	Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients	0	None
2010-04-17	Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH	0	None
2010-04-17	New data on Cladribine Tablets presented at AAN annual meeting	0	None
2010-04-17	Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009	0	None
2010-04-17	Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL	0	3.7
2010-04-17	RegeneRx Biopharmaceuticals proposes common stock public offering	0	None
2010-04-16	Repligen expects total revenue of $21.0M for fiscal year 2010	0	None
2010-04-16	VisEn Medical expands FMT imaging platform	0	None
2010-04-16	Results of study comparing REMICADE to azathioprine for Crohn's disease published	0	None
2010-04-16	InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL	0	None
2010-04-16	Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment	0	None
2010-04-16	Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV	0	None
2010-04-16	Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting	0	None
2010-04-16	Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL	0	None
2010-04-16	Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial	0	None
2010-04-16	Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate	0	None
2010-04-16	Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting	0	None
2010-04-16	Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting	0	5
2010-04-16	LOTS results of Myozyme in older children and adults with Pompe disease published	0	None
2010-04-16	Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies	0	None
2010-04-16	Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066	0	None
2010-04-16	Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222	0	None
2010-04-16	Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN	0	None
2010-04-15	Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422	0	None
2010-04-15	Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting	0	None
2010-04-15	Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine	0	None
2010-04-15	AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting	0	1
2010-04-15	Investment report on MIPI	0	None
2010-04-15	Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting	0	None
2010-04-15	Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV	0	None
2010-04-15	Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting	0	None
2010-04-15	Phase I clinical trial of DFMO initiated to treat children with neuroblastoma	0	None
2010-04-15	Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients	0	None
2010-04-15	Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights	0	None
2010-04-15	Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients	1	None
2010-04-15	Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting	0	None
2010-04-15	Kenta Biotech presents positive Phase IIa results of panobacumab	0	None
2010-04-15	Targeted therapy MDV3100 is effective for patients with CRPC: Study	0	None
2010-04-15	Opexa Therapeutics presents key efficacy data on Tovaxin	0	None
2010-04-15	Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD	0	None
2010-04-15	Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction	0	None
2010-04-15	Phase IIa clinical trial results of Serdaxin for treatment of MDD	0	None
2010-04-15	Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced	0	None
2010-04-15	ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals	0	None
2010-04-15	Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors	0	None
2010-04-15	First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial	0	None
2010-04-15	Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure	0	None
2010-04-13	EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer	0	None
2010-04-13	Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting	0	None
2010-04-13	VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings	0	None
2010-04-13	Investment report on Rexahn Pharmaceuticals	0	None
2010-04-13	NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS	0	None
2010-04-13	Gilead Sciences doses first patient in Quad Phase III clinical program	0	None
2010-04-12	Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting	0	None
2010-04-12	XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting	0	None
2010-04-12	Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID	0	None
2010-04-12	Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles	0	None
2010-04-12	Results of Phase I ThermoDox dose escalation trial to be discussed in a press conference	0	None
2010-04-12	Clinical and preclinical malaria vaccine data presented at Keystone Symposium	0	None
2010-04-12	Phase I study of Affinium Pharmaceuticals' AFN-1252 for MRSA initiated	0	None
2010-04-12	Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin	0	None
2010-04-09	Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference	0	None
2010-04-09	Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting	0	None
2010-04-09	ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor	0	None
2010-04-09	Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting	0	None
2010-04-09	Combination telaprevir treatment beneficial for retreatment of hepatitis C	0	None
2010-04-09	Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis	0	None
2010-04-09	Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease	0	5
2010-04-09	Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine	0	None
2010-04-09	University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma	0	None
2010-04-09	Æterna Zentaris commences perifosine Phase 3 registration trial	0	None
2010-04-09	ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer	0	None
2010-04-08	Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD	0	None
2010-04-08	Phase 1 SAD study of PSI-938 for HCV initiated	0	5
2010-04-08	OncoGenex Pharmaceuticals recognized with BIOTECanada's Gold Leaf Award	0	None
2010-04-08	Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine	0	None
2010-04-08	Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection	0	None
2010-04-08	Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated	0	None
2010-04-08	Results of M118 EMINENCE clinical trial published in Circulation	0	None
2010-04-08	Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme	0	None
2010-04-08	Encouraging results from OptiNose's sumatriptan Phase II study for migraine	0	None
2010-04-08	MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE	0	None
2010-04-08	Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18	0	None
2010-04-07	King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain	0	1
2010-04-07	Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda	0	None
2010-04-07	Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer	0	4
2010-04-07	MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting	0	None
2010-04-07	Nile Therapeutics to fund ongoing Phase II clinical trial of CD-NP with proposed public offering	0	None
2010-04-07	Nationwide Phase III clinical trial of OncoVEX for advanced melanoma	0	None
2010-04-07	Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID	0	None
2010-04-07	MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone	0	None
2010-04-06	Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting	0	None
2010-04-05	Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation	0	None
2010-04-05	Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD	0	None
2010-04-05	Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing	0	None
2010-04-05	Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure	0	None
2010-04-05	Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009	0	None
2010-04-03	Clinical utility and pharmacological action of MN-166 in treatment of MS	0	None
2010-04-03	CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer	0	None
2010-04-02	Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate	0	None
2010-04-01	Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development	0	5
2010-04-01	Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment	0	None
2010-04-01	BELLUS Health initiates Phase I clinical study for NRM8499	0	None
2010-04-01	Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US	0	3
2010-04-01	Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study	0	None
2010-04-01	Positive results from Phase 2 clinical trial of OMS103HP	0	None
2010-04-01	Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout	0	None
2010-03-31	Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer	0	5
2010-03-31	ViroPharma initiates Phase 2 clinical study to evaluate Cinryze	0	None
2010-03-31	DSMB for DIGNITY trial recommends Celsion continue enrollment	0	None
2010-03-31	ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC	0	None
2010-03-31	Investment report on Sunesis Pharmaceuticals	0	None
2010-03-31	SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference	0	3
2010-03-31	Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data	0	None
2010-03-31	PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic	0	None
2010-03-31	QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations	0	None
2010-03-31	YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387	0	None
2010-03-31	Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction	0	None
2010-03-30	FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine	0	1
2010-03-30	NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss	0	None
2010-03-30	CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN	0	None
2010-03-30	Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD	0	None
2010-03-30	GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer	0	None
2010-03-30	Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA	0	None
2010-03-29	NexMed files IND with FDA for Phase II trial of PrevOnco for HCC	0	None
2010-03-29	Interim data comparing Cervista HPV HR to Hybrid Capture 2 presented at 4th Biennial Meeting of AOGIN	0	None
2010-03-29	Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced	0	None
2010-03-29	Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress	0	4
2010-03-29	Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD	0	None
2010-03-29	Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC	0	None
2010-03-29	Genta reports net loss of $11.7M for fourth-quarter 2009	0	None
2010-03-29	ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009	0	None
2010-03-26	Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy	0	None
2010-03-26	Avid, Cardinal Health partner to detect Alzheimer's disease in living patients	1	None
2010-03-26	Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow	0	None
2010-03-26	NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy	0	None
2010-03-26	Cedars-Sinai investigators to study tadalafil as treatment for progressive muscle disease	0	None
2010-03-26	Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV	0	None
2010-03-26	Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule	0	None
2010-03-26	Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced	0	None
2010-03-26	FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD	0	None
2010-03-26	Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine	0	None
2010-03-26	Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX	0	None
2010-03-26	Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C	0	None
2010-03-26	Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial	0	None
2010-03-26	Aastrom Biosciences' RESTORE-CLI trial: Final patient treated	0	None
2010-03-26	DARA BioSciences announces the initiation of Phase I clinical study for DB959	0	None
2010-03-25	Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916	0	None
2010-03-25	Scott & White seeks breast cancer patients for Phase II clinical trial	0	None
2010-03-25	Biogen Idec and Elan begin comparative trial of MS treatments	0	5
2010-03-25	Clinic sites seek gay men to participate in HIV vaccine study	0	None
2010-03-25	Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference	0	None
2010-03-24	Shingles drug receives clearance for final stage of testing	0	None
2010-03-24	Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study	0	None
2010-03-24	CytoDyn provides additional funds for HIV/AIDS drug trial	0	None
2010-03-23	Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery	0	None
2010-03-23	Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases	0	None
2010-03-23	Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily	0	None
2010-03-23	Inhibitex announces net loss of $4.7M for fourth-quarter 2009	0	None
2010-03-23	Aradigm reports net loss of $3.4M for fourth-quarter 2009	0	None
2010-03-23	Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands	0	None
2010-03-23	CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval	0	None
2010-03-23	Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years	0	None
2010-03-22	Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated	0	None
2010-03-22	Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine	0	None
2010-03-22	ChemoCentryx undertakes Phase II clinical trial of CCX140	0	None
2010-03-22	First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat	0	None
2010-03-22	Simcere Pharmaceutical completes Phase IV clinical study of Endostar	0	None
2010-03-22	Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1	0	None
2010-03-22	PharmAthene suspends work on SparVax research and development contract with BARDA	0	None
2010-03-22	Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate	0	None
2010-03-22	Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out	0	None
2010-03-19	Major study shoots for personalized breast cancer drugs	0	5
2010-03-19	CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement	0	None
2010-03-19	Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients	0	None
2010-03-19	A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter	0	None
2010-03-19	Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010	0	None
2010-03-19	FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched	0	None
2010-03-19	Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056	0	None
2010-03-19	ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation	0	None
2010-03-18	Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints	0	None
2010-03-18	Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series	0	None
2010-03-18	Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study	0	None
2010-03-18	Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD	0	None
2010-03-18	Findings from Study 305 evaluating the effect of Northera reported	0	None
2010-03-18	Agendia to participate in groundbreaking clinical trial for breast cancer	0	None
2010-03-18	Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin	0	None
2010-03-17	Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction	0	None
2010-03-17	ONGLYZA-metformin combination: FDA accepts NDA for review	0	2
2010-03-17	Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC	0	None
2010-03-17	Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002	0	None
2010-03-17	Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar	0	None
2010-03-17	Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD	0	None
2010-03-17	Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint	0	None
2010-03-17	Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications	0	None
2010-03-17	Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC	0	None
2010-03-17	TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene	0	None
2010-03-17	Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution	0	None
2010-03-17	Booster shot appears to improve TB resistance in previously vaccinated adults	0	None
2010-03-17	Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting	0	None
2010-03-16	PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients	0	None
2010-03-16	Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients	1	2.5
2010-03-16	Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent	0	3
2010-03-16	Iverson Genetic Diagnostics to conduct WARFARIN clinical study	0	None
2010-03-16	Promedior raises $12M in Series C financing	0	None
2010-03-16	EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin	0	3
2010-03-16	Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint	0	None
2010-03-16	Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis	0	5
2010-03-16	Positive results from Phase IIa epilepsy study of ICA-105665	0	None
2010-03-15	Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development	0	None
2010-03-15	CytRx plans five Phase 2 clinical trials with oncology drug candidates	0	None
2010-03-15	YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR	0	None
2010-03-15	Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis	0	None
2010-03-15	Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study	0	None
2010-03-15	Data from ACCORD Lipid study: Abbott issues statement	0	None
2010-03-15	Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly	0	None
2010-03-15	Regadenoson drug is safe for heart transplant patients: Study	0	None
2010-03-15	XOMA 052 reduces adverse consequences that lead to development of congestive heart failure	0	None
2010-03-15	ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes	0	None
2010-03-12	XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients	0	5
2010-03-12	TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints	0	None
2010-03-12	Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009	0	None
2010-03-12	CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk	0	None
2010-03-12	Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010	0	None
2010-03-12	AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy	0	None
2010-03-12	Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints	0	None
2010-03-12	Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy	0	None
2010-03-12	Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC	0	None
2010-03-12	Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug	0	None
2010-03-12	Genentech announces topline results from Phase III trial of Avastin	0	None
2010-03-12	PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS	0	None
2010-03-12	Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL	0	None
2010-03-11	FDA provides guidance on Restanza clinical program in treatment of CABP	0	4.7
2010-03-11	Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%	0	None
2010-03-11	Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study	0	None
2010-03-11	Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression	0	None
2010-03-11	Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage	0	None
2010-03-11	NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil	0	4
2010-03-11	Lithera announces positive results from Phase IIa clinical study of LIPO-102	0	None
2010-03-10	Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial	0	None
2010-03-10	NeoPharm seeks Orphan Drug Designation for IL13-PE38QQR in treatment of IPF	0	None
2010-03-10	Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment	0	None
2010-03-10	Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009	0	None
2010-03-10	Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide	0	None
2010-03-10	AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B	0	None
2010-03-10	Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010	0	None
2010-03-10	Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program	0	None
2010-03-10	Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes	0	None
2010-03-10	Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies	0	None
2010-03-09	Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV	0	None
2010-03-09	Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury	0	None
2010-03-09	Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK	0	None
2010-03-09	JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK	0	None
2010-03-09	Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray	0	None
2010-03-08	ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC	0	None
2010-03-08	Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009	0	None
2010-03-08	Rexahn Pharmaceuticals granted Japanese patent for Archexin	0	None
2010-03-08	Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer	0	None
2010-03-08	NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete	0	None
2010-03-08	Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC	0	None
2010-03-08	VIVUS granted three additional patents for Qnexa	0	None
2010-03-08	Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals	0	None
2010-03-08	DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test	0	None
2010-03-08	Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting	0	None
2010-03-06	Presentation of results from open-label extension study of Xenazine	0	None
2010-03-06	Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results	0	None
2010-03-05	LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting	0	None
2010-03-05	Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced	0	4
2010-03-05	Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients	0	5
2010-03-05	Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented	0	None
2010-03-04	BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine	0	3.2
2010-03-04	Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs	0	None
2010-03-04	Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue	0	None
2010-03-04	Belatacept drug can prevent graft rejection in kidney transplant recipients	0	None
2010-03-04	Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments	0	None
2010-03-04	Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001	0	None
2010-03-04	Endocyte's PRECEDENT study: DSMB recommends enrollment to continue	0	None
2010-03-04	Androxal Type C meeting: Repros Therapeutics receives FDA’s version of minutes	0	None
2010-03-04	Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed	0	None
2010-03-04	Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA	0	None
2010-03-03	Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer	0	5
2010-03-03	AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement	0	None
2010-03-03	Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients	0	None
2010-03-03	FDA issues new draft guidance for Trius Therapeutics' proposed Phase 3 trial of torezolid phosphate	0	None
2010-03-03	Merck’s MF/F Phase III study data presented at AAAAI annual meeting	0	None
2010-03-03	Merck announces updated late-stage pipeline following its recent merger with Schering-Plough	0	5
2010-03-03	Phase III study results of Merck's allergy immunotherapy tablet	0	None
2010-03-02	Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB	0	None
2010-03-02	Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development	0	None
2010-03-02	Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial	0	None
2010-03-02	Archimedes Pharma raises GBP65 million in new funding	0	None
2010-03-02	IgPro20 protects PI patients against infection	0	None
2010-03-02	PTSD drug: Cannabis Science to file first application for FDA clinical trials	0	None
2010-03-02	Celsion to commence Phase II Study of ThermoDox and RFA for CRLM	0	None
2010-03-02	Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION	0	None
2010-03-01	Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment	0	None
2010-03-01	Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline	0	None
2010-03-01	[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment	0	None
2010-02-27	ADMET tester Absorption Systems joins Society of Toxicology as Affiliate	0	4
2010-02-27	Single submission of orphan drug designation annual report for both FDA and EMA	0	2
2010-02-27	Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090	0	None
2010-02-26	Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients	0	None
2010-02-26	Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB	0	None
2010-02-26	Study confirms efficacy and tolerability of lacosamide for uncontrolled POS	0	None
2010-02-26	Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients	0	5
2010-02-26	Genta initiates new dose-ranging study of tesetaxel drug	0	None
2010-02-25	Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC	0	None
2010-02-25	Cannabis Science completes selection of initial cannabis-based pharmaceutical for FDA clinical trials	0	None
2010-02-25	OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC	0	None
2010-02-25	Study demonstrates Prochymal treamtent is safe for cardiac patients	0	None
2010-02-25	Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy	0	None
2010-02-25	Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV	0	None
2010-02-24	Welichem commences enrollment in WBI-1001 Phase IIa clinical trial for psoriasis	0	None
2010-02-24	Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients	0	None
2010-02-24	Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint	0	None
2010-02-24	Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting	0	5
2010-02-24	Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference	0	None
2010-02-24	ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI	0	5
2010-02-24	Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy	0	None
2010-02-23	Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction	0	4.5
2010-02-23	Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients	0	None
2010-02-23	Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes	0	None
2010-02-23	TCAD therapy active and synergistic against drug resistant influenza virus strains	0	None
2010-02-23	Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint	0	None
2010-02-23	GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae	0	None
2010-02-23	Viamet Pharmaceuticals, Novartis Option Fund partner to develop novel inhibitors against key metalloenzyme target	0	None
2010-02-23	Heartware completes patient enrollment for ADVANCE clinical trial	0	None
2010-02-23	Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC	0	None
2010-02-23	Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development	0	None
2010-02-22	Enzymerx completes enrollment for clinical trial of pegsitacase	0	None
2010-02-22	FDA grants Fast Track designation for Curemark's CM-AT autism treatment	0	None
2010-02-22	Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection	0	None
2010-02-20	Emory School of Medicine to enroll nearly 1,140 people for Phase III clinical trial of progesterone for TBI	0	None
2010-02-19	Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria	0	None
2010-02-19	BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines	0	None
2010-02-19	Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting	0	None
2010-02-19	BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting	0	None
2010-02-18	Incyte announces 2009 financial results and key fourth-quarter accomplishments	0	None
2010-02-18	Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME	0	None
2010-02-18	PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity	0	None
2010-02-18	Aprea's AML treatment receives EMEA recommendation for orphan drug status	0	None
2010-02-18	Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla	0	None
2010-02-18	Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers	0	None
2010-02-18	Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010	0	None
2010-02-17	Roche completes enrollment in RG7128 Phase 2b PROPEL study	0	None
2010-02-17	Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline	0	None
2010-02-17	FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients	0	4.2
2010-02-17	Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes	0	None
2010-02-17	Fourth-quarter and full-year 2009 results announced by Celsion	0	None
2010-02-17	Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer	0	None
2010-02-17	Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer	0	5
2010-02-17	ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study	0	None
2010-02-17	Generx clinical development opportunities: bioRASI to assist Cardium	0	None
2010-02-16	Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB	0	None
2010-02-16	Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced	0	None
2010-02-16	Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial	0	3
2010-02-16	MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial	0	None
2010-02-16	Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency	0	None
2010-02-14	Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study	0	None
2010-02-12	Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis	0	None
2010-02-12	Viral Genetics: Company update	0	None
2010-02-12	Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial	0	None
2010-02-12	Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity	1	5
2010-02-12	Third party reexamination of Phase III study of Ereska meets primary endpoint	0	None
2010-02-12	Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease	0	None
2010-02-12	Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease	0	None
2010-02-12	NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services	0	None
2010-02-12	Second-quarter fiscal 2010 results announced by Pharmacyclics	0	None
2010-02-12	Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented	0	None
2010-02-11	Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease	0	None
2010-02-11	PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study	0	None
2010-02-11	3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA	0	None
2010-02-11	YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference	0	None
2010-02-11	Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel	0	None
2010-02-11	4SC AG announces the first treatment in Phase I clinical study of 4SC-205	0	None
2010-02-11	Micromet outlines the design of registration study for blinatumomab in ALL	0	None
2010-02-11	MUHC commences clinical trial of Exsulin for type 1 diabetes	0	5
2010-02-11	QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR	0	None
2010-02-10	Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium	0	None
2010-02-10	DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer	0	None
2010-02-10	Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint	0	None
2010-02-10	Positive results from Naurex's Phase I clinical trial of GLYX-13 reported	0	None
2010-02-10	Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International	0	None
2010-02-10	DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx	0	None
2010-02-10	QR Pharma commences clinical trial of Posiphen in early stage AD patients	0	None
2010-02-10	Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial	0	None
2010-02-10	Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C	0	4.3
2010-02-10	TI commences Phase IIa clinical trial for its lead molecule in CDH	0	None
2010-02-10	Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction	0	5
2010-02-10	Advaxi to receive fund from CRUK for clinical trial of ADXS11-001	0	None
2010-02-10	FDA expands indication for Crestor	0	None
2010-02-09	Thrombogenics announces publication of positive microplasmin Phase II trial results	0	None
2010-02-09	USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza	0	None
2010-02-09	Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir	0	None
2010-02-09	Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule	0	None
2010-02-09	Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases	0	None
2010-02-09	Novavax announces new data from trivalent seasonal influenza VLP vaccine study	0	None
2010-02-09	GeoVax Labs provides updates on HIV-1 vaccine trials	0	None
2010-02-09	Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial	0	None
2010-02-09	Genta commences Phase 2 trial of tesetaxel on first subject	0	None
2010-02-09	Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions	0	None
2010-02-08	Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial	0	None
2010-02-08	Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study	0	None
2010-02-05	CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF	0	None
2010-02-05	EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award	0	None
2010-02-05	BioTime announces results of independent Hextend study in hemodynamically unstable trauma patients	0	None
2010-02-05	Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients	0	None
2010-02-05	BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome	0	None
2010-02-05	WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial	0	None
2010-02-05	Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529	0	None
2010-02-04	Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced	0	None
2010-02-04	Results from three phase two studies show the effectiveness of Tanezumab	1	None
2010-02-04	Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium	0	None
2010-02-04	Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced	0	None
2010-02-04	Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability	0	None
2010-02-04	Phase 2a clinical trial results of VX-809 in patients with CF announced	0	None
2010-02-03	Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401	0	None
2010-02-03	Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications	0	4
2010-02-03	Adcirca now available in Canada for treatment of pulmonary arterial hypertension	0	None
2010-02-03	MV vaccine prevents TB in people with HIV infection	0	None
2010-02-03	Promising results from Soligenix' RiVax vaccine trials against ricin toxin	0	None
2010-02-03	Repros Therapeutics receives FDA confirmation for initiating Androxal IND	0	None
2010-02-03	Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement	0	None
2010-02-02	GenSpera’s G-115 anti-cancer drug awarded US patent	0	None
2010-02-02	Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia	0	None
2010-02-02	RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation	0	None
2010-02-02	Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint	0	None
2010-02-02	Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel	0	None
2010-02-01	Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza	0	None
2010-02-01	Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease	0	3
2010-01-30	Clinical results of MedImmune's pivotal trial for motavizumab published	0	None
2010-01-30	Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia	0	None
2010-01-29	Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced	0	None
2010-01-29	New guidance may help minimize risks to patient privacy in clinical trials	0	None
2010-01-29	Diabetes vaccine: Diamyd Medical to file for market approval in 2011	0	None
2010-01-29	Merge Healthcare deploys etrials eDiary 5.0 platform for global urology clinical trial	0	None
2010-01-28	Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV	0	None
2010-01-28	ChemoCentryx announces the initiation of Phase I clinical trial of CCX168	0	None
2010-01-28	Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis	0	None
2010-01-28	NIDA supports Omeros' Addiction program	0	None
2010-01-28	Neovasc to fund proceeds of its non-brokered private placement for COSIRA trial	0	None
2010-01-28	Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases	0	None
2010-01-28	Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference	0	None
2010-01-28	Men welcome male contraceptive pill currently undergoing trials	0	None
2010-01-28	GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients	0	None
2010-01-27	Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD	0	None
2010-01-27	GenSpera commences treatment in G-202 Phase I trial for solid tumors	0	None
2010-01-27	Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development	0	None
2010-01-27	Cornerstone Pharmaceuticals closes $6.17M Series B-4 private equity financing	0	None
2010-01-27	Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010	0	None
2010-01-27	Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes	0	1
2010-01-27	Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection	0	None
2010-01-27	Curemark commences CM-AT Phase III autism clinical trial enrollment at ten sites	0	None
2010-01-27	YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment	0	None
2010-01-25	Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B	0	None
2010-01-24	Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced	0	None
2010-01-23	Pfizer reports final results from randomized Phase 3 trial of Sutent	0	None
2010-01-22	Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial	0	None
2010-01-22	Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced	0	None
2010-01-22	CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent	0	None
2010-01-21	Ipsen and Inspiration Biopharmaceuticals form strategic partnership	0	None
2010-01-21	Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC	0	None
2010-01-21	China Pharma Holdings announces completion of clinical trials for Candesartan	0	None
2010-01-21	Elevation Pharmaceuticals closes $30M tranched Series A financing	0	None
2010-01-21	Pharmasset commences PSI-7977 Phase 2a trial for HCV	0	None
2010-01-21	BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial	0	None
2010-01-21	Results of two pivotal Phase III clinical trials with oral FTY720 published	0	None
2010-01-21	Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced	0	None
2010-01-21	IMUC’s ICT-107 vaccine product candidate targets cancer stem cells	0	5
2010-01-21	EMD Serono announces results from CLARITY Phase III trial in MS patients	0	None
2010-01-21	Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced	0	None
2010-01-20	Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients	0	None
2010-01-20	PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference	0	None
2010-01-20	Telaprevir effective in HCV patients	4	3
2010-01-20	PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD	0	None
2010-01-20	Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes	0	None
2010-01-20	Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed	0	None
2010-01-20	Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment	0	None
2010-01-20	Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced	0	5
2010-01-19	CytoDyn commences enrollment in Cytolin clinical trial	0	None
2010-01-19	DURECT commences dosing in its POSIDUR Phase III clinical trial	0	None
2010-01-19	Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies	0	None
2010-01-19	PCI Biotech AS completes second dose group in phase I/II study of Amphinex	0	None
2010-01-19	Enrollment of Phase 2 portion of Cempra Pharmaceuticals' Phase 2/3 clinical trial of TAKSTA completed	0	None
2010-01-18	New neuroprotective drug trial for people with traumatic brain injuries	0	None
2010-01-18	AVIR Green Hills Biotechnology commences deltaFLU Phase II study	1	None
2010-01-18	Treatment for chronic hepatitis C with pegylated-interferon and ribavirin proves effective	0	None
2010-01-17	Results from Bionovo's phase 1B clinical trial of Bezielle published	0	None
2010-01-13	Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1	0	5
2010-01-13	New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic	0	None
2010-01-13	Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials	0	None
2010-01-12	Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed	0	None
2010-01-12	Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial	0	None
2010-01-12	Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer	0	None
2010-01-12	Phase I clinical trial of XRX-001 for yellow fever initiated	0	None
2010-01-12	Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV	0	None
2010-01-12	HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C	0	None
2010-01-12	Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion	0	None
2010-01-12	Salt Lake City research center joins international drug trial program for painful menstrual cramps	0	None
2010-01-12	CEL-SCI completes validation of its GMP manufacturing facility	0	None
2010-01-12	NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration	0	None
2010-01-12	Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine	0	None
2010-01-12	4SC commences treatment in its resminostat Phase II trial for HL	0	None
2010-01-12	Idenix Pharmaceuticals announces significant progress in HCV development programs	0	None
2010-01-12	Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA	0	None
2010-01-12	YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration	0	None
2010-01-12	Pfizer commences SBI-087 Phase 2 clinical trial for RA	0	None
2010-01-12	Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel	0	None
2010-01-12	Positive results from KemPharm's KP106 Phase 1 clinical trial for ADHD	0	None
2010-01-12	Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported	0	None
2010-01-12	BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD	0	None
2010-01-11	Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced	0	None
2010-01-11	Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics	0	None
2010-01-11	Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease	0	None
2010-01-11	New data from phase 3 study of avanafil for treatment of ED announced	3	5
2010-01-11	Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published	0	None
2010-01-11	Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy	0	None
2010-01-09	Results of randomized, placebo-controlled study of Ambrotose complex announced	0	None
2010-01-09	Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development	0	None
2010-01-09	LFB completes conversion of all acquired preferred stock	0	None
2010-01-09	Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma	0	3.2
2010-01-09	Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track	0	None
2010-01-08	Funxional Therapeutics completes Phase I study of FX125L	0	None
2010-01-08	TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial	0	5
2010-01-08	Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer	0	5
2010-01-08	Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study	0	None
2010-01-08	Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed	0	None
2010-01-08	University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD	0	None
2010-01-08	Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced	0	5
2010-01-08	Initiation of double blind placebo controlled multi-center trial of DAS181 announced	0	None
2010-01-08	Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab	0	None
2010-01-07	Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced	0	None
2010-01-07	Positive top-line results from Phase III study of aclidinium bromide announced	0	None
2010-01-07	BioVex's Phase 3 melanoma study amended to include first line patients	0	None
2010-01-07	Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced	0	5
2010-01-07	Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective	0	None
2010-01-06	Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38	0	None
2010-01-06	Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206	0	None
2010-01-06	OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427	0	None
2010-01-06	Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results	0	None
2010-01-06	Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244	0	4
2010-01-06	Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex	0	None
2010-01-06	Phase I clinical trial for Intellikine's INK128 inhibitor initiated	0	None
2010-01-06	Scott & White's CRI launches two clinical trials targeting cancers	0	None
2010-01-06	Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001	0	None
2010-01-06	EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124	0	None
2010-01-06	IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090	0	None
2010-01-06	Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4	0	None
2010-01-06	Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced	0	None
2010-01-05	DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002	0	None
2010-01-05	Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated	0	None
2010-01-05	Talampanel slows progression of amyotrophic lateral sclerosis	0	None
2010-01-04	Headline results from first phase III study of Balaglitazone announced	0	None
2010-01-04	DSPA submits lurasidone NDA to the FDA	0	None
2010-01-04	BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma	0	None
2010-01-04	Novelos continues NOV-002 Phase 3 combination trial for lung cancer	0	5
2010-01-03	D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke	0	5